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1. Abbreviations
Table 1.: List ob abbreviations
Abbreviation Long name
ALL All ﬁve diseases (AS, CD, PS, PSC, UC)
AS ankylosing spondylitis
BED Browser Extensible Data
CD Crohn’s disease
CHR chromosome
CPDB ConsensusPathDB
DAVID The Database for Annotation, Visualization
and Integrated Discovery (Enrichment tool)
DEPICT Data-driven Expression Prioritized Integra-
tion for Complex Traits (software)
DNA deoxyribonucleic acid
EGF epidermal growth factor
EGFR epidermal growth factor receptor
ENCODE Encyclopedia of DNA Elements
eQTL expression quantitative trait locus
ESR estrogen receptor
et al. and others (Latin: et alii)
FDR false discovery rate
GO Gene Ontology
GOTERM Gene Ontology term
GWA genome-wide association
GWAS genome-wide association study/studies
HGNC HUGO Gene Nomenclature Committee
HLA human leukocyte antigen (synonymous with
MHC in humans)
(continued on next page)
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(continued from previous page)
HUMAN In the case of UniProt IDs: A protein being
part of the human proteome
IBD inﬂammatory bowel disease
ID identiﬁer
IIBDGC International IBD genetics consortium
IMSGC International MS genetics consortium
KEGG Kyoto Encyclopedia of Genes and Genomes
LCC largest connected component (in a network)
LD linkage disequilibrium
MHC major histocompatibility complex (synony-
mous with HLA in humans)
MS multiple sclerosis
NCBI National Center for Biotechnology Informa-
tion
OR odds ratio
PINBPA Protein interaction network-based pathway
analysis (also the name of a Cytoscape plugin)
PIN protein interaction network
PPI protein-protein interaction(s)
PSC primary sclerosing cholangitis
PS psoriasis
RNA ribonucleic acid
SBM Subset-based meta-analysis
SNP single nucleotide polymorphism
SNV single nucleotide variation
TF transcription factor
TFBS transcription factor binding site
(continued on next page)
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UC ulcerative colitis
UniProt Universal Protein Resource (uniprot.org)
VEGAS Versatile Gene-Based Test for Genome-wide
Association Studies (software)
vii
Contents
1. Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
1. Introduction 1
1.1. Genome-wide association studies (GWAS) . . . . . . . . . . . . . . . . . 2
1.2. Inﬂammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.3. Complex Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.4. Networks as a Response to Complex Diseases . . . . . . . . . . . . . . . 9
1.5. Introduction to protein-protein interaction networks . . . . . . . . . . . . 12
1.5.1. Characteristics of protein-protein interaction networks . . . . . . 13
1.5.2. Centralities (importance of nodes in networks) . . . . . . . . . . . 14
1.5.3. Pathways and Modules . . . . . . . . . . . . . . . . . . . . . . . . 15
1.6. Enrichment of terms and tissues based on gene lists . . . . . . . . . . . . 17
1.7. Objectives of this Thesis . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2. Material & Methods 19
2.1. SNPs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.2. Protein-Protein Interaction Reference Databases . . . . . . . . . . . . . . 22
2.3. Mapping of SNPs to Genes . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.4. ID mapping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.5. Network handling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.5.1. Cytoscape . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.5.2. Eﬀect directions of SNPs on the network level . . . . . . . . . . . 31
2.5.3. Network randomization . . . . . . . . . . . . . . . . . . . . . . . . 31
2.6. Term- and Tissue-Enrichment . . . . . . . . . . . . . . . . . . . . . . . . 33
3. Results 35
3.1. Common Network Modules Across Inﬂammatory Diseases . . . . . . . . . 36
3.1.1. SNP to Gene Mapping . . . . . . . . . . . . . . . . . . . . . . . . 36
3.1.2. Disease networks . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
viii
3.1.3. Protein-interaction-network–based pathway analysis (PINBPA) . 40
3.1.4. Gene-wise Overlap Between Diseases in Networks . . . . . . . . . 49
3.2. Geneset-based networks . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.2.1. Geneset enrichment . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.2.2. Tissue enrichment . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.2.3. Geneset-based networks . . . . . . . . . . . . . . . . . . . . . . . 68
3.2.4. Enrichment Analyses . . . . . . . . . . . . . . . . . . . . . . . . . 71
3.2.5. Disease-speciﬁc subnetworks . . . . . . . . . . . . . . . . . . . . . 75
3.2.6. Linker nodes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
3.3. Eﬀect directions of Single Nucleotide Polymorphisms . . . . . . . . . . . 83
3.3.1. Mapping of SNPs to genes/DNA binding elements . . . . . . . . . 87
3.3.2. Relationships between transcriptional regulators and SNPs . . . . 88
3.3.3. Purely Protective Binding Factors . . . . . . . . . . . . . . . . . . 89
3.3.4. Protective genes in detail . . . . . . . . . . . . . . . . . . . . . . . 94
3.3.5. Comparison with geneset-based networks . . . . . . . . . . . . . . 97
3.3.6. Network analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
4. Discussion 105
4.1. Biology of Inﬂammatory Diseases . . . . . . . . . . . . . . . . . . . . . . 105
4.1.1. Networks of Inﬂammatory Diseases . . . . . . . . . . . . . . . . . 107
4.1.2. Representation of Biology in Networks . . . . . . . . . . . . . . . 109
4.2. Mapping of SNPs to genes . . . . . . . . . . . . . . . . . . . . . . . . . . 112
4.3. Construction of Networks . . . . . . . . . . . . . . . . . . . . . . . . . . 115
4.3.1. Finding subnetworks and submodules . . . . . . . . . . . . . . . . 116
4.4. Enrichment Findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
4.5. Methodological Considerations . . . . . . . . . . . . . . . . . . . . . . . . 121
4.5.1. Automation, Reproducibility and Repeatability . . . . . . . . . . 122
4.6. Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
5. Conclusions 126
A. Zusammenfassung 128
B. Summary 130
C. Supplementary Chapters 131
C.1. A few notes on the Microbiome . . . . . . . . . . . . . . . . . . . . . . . 131
C.2. Modiﬁcations to VEGAS . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
ix
Contents x
List of figures 134
List of tables 138
Bibliography 140
Chapter 1.
Introduction
“Look at me: still talking when there’s science to do! When I look out
there, it makes me glad I’m not you.”
— Mad robot GLaDOS (Lyrics)
Human health is dependent on many factors. On the highest level, these factors can
be divided into inborn and environmental factors. Inborn factors include genetics and
epigenetics while environmental factors include (but are not limited to) exposure to other
organisms as well as to chemicals. These other organisms may be viruses, microorganisms
or higher organisms. Chemicals include food and non-food products.
Another environmental factor is radiation. But it is usually not a highly inﬂuential
factor, even though sunlight is relevant for vitamin D production3 and skin cancer4.
There can be an interplay between these factors. Pathogens and symbionts can
coevolve with their hosts and take advantage of the genetic architecture that is common
in a human population5.
Understanding the etiology of a disease can therefore require an understanding of
the inborn and environmental factors that drive the disease. However, this thesis only
focusses on the genetic aspects of inﬂammatory diseases. Environmental factors will only
be brieﬂy discussed.
1
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1.1. Genome-wide association studies (GWAS)
In order to understand the genetic factors that drive disease, it has to be determined
which parts of the genome are responsible for a certain phenotype. The human genome
is about 3.2 billion base pairs long6 and unfortunately it is far from trivial to understand
what these base pairs do.
Almost every human has a unique genomic sequence6. But this genomic sequence
is still very similar to every other human’s genomic sequence. Yet the variations in
the human genome can lead to major diﬀerences in the development and health of
individuals7.
The smallest variations in the genome are called single nucleotide polymorphisms
(SNPs). They describe the variability of a single nucleotide at a speciﬁc position in the
genome under the condition that each of the observed nucleotides must be present in at
least 1% of the population8.
In order to assess the relevance of a SNP for a disease, statistical methods can be
applied to show that the presence or the absence of a SNP correlates well with the
presence or the absence of a disease. A modern statistical method for assessing the
relevance of a SNP for several diseases at once is the Subset-based Meta-analysis (SBM)9.
It should be noted that there is positive and negative association. If the variant that is
less frequent in the population is negatively correlated with the presence of a disease, the
variant is considered to be protective against that disease. In a similar fashion, if the less
frequent variant is positively correlated, it is regarded as risk-increasing for developing
the disease (see also Figure 1.1).
When trying to understand which SNPs inﬂuence a disease, it usually makes sense
to test all known SNPs in the genome for association. Such an endeavor is called a
genome-wide association study (GWAS). It is commonly said that such a GWAS is
hypothesis-free 10 because all SNPs in the genome are regarded as potentially equally
qualiﬁed to contribute to the disease. However, the term hypothesis-free is actually not
correct in the statistical sense of the word, because hypothesises are statements that are
being tested with statistical tests. In a typical genome-wide association study there are
usually about one million (or more) statistical hypothesises: For every SNP it is being
tested if it is not associated with a disease (Null hypothesis)11.
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Figure 1.1.: Risk alleles of inflammatory bowel disease (IBD) and it’s subtypes Crohn’s disease
(CD) and ulcerative colitis (UC) based on the 163 SNPs from Jostins et al.7.
The frequency of the risk alleles in the population is shown on the x-axis. The
corresponding odds ratio for every risk allele is shown on the y-axis with most
alleles being below an OR of 1.3 which reflects on their modest effect sizes. This
image was first published by Ellinghaus et al1 as Figure 1.
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When doing statistics, sample size is a major concern. More genotypes of people can
lead to stronger statistical evidence of the inﬂuence of a SNP on a disease. However,
sequencing complete genomes is still relatively expensive and sequencing tens of thousands
of people is even more so. To work around this problem, no complete sequencing is
done and instead only a subset of SNPs are genotyped. This subset of SNPs consists of
so-called marker SNPs. They allow us to infer the remaining SNPs by a process called
imputation 12.
The idea behind imputation is that SNPs are coupled due to linkage disequilibrium
(LD). The cause of LD is based on the principle that genetic information in humans is
transferred on chromosomes. A chromosome is transferred as one unit of inheritance to
the next generation together with all SNPs on it, hence SNPs are coupled11. However,
this is not the complete picture. During meiosis the homologous chromosomes pair up
and exchange parts of their DNA sequence. This process is called crossing over. Through
crossing over some SNPs can be transferred from one chromosome to another and the
coupling is broken. The greater the distance between two SNPs, the more likely it is
that there is a crossing over event between them. It is therefore said that two SNPs,
which are close to each other, are in high LD, because it is unlikely that they will be
separated by a crossing over event. High LD allows the assumption that if one SNP is
being observed, the other will also be present and thus does not need to be genotyped11.
As stated previously, a genome-wide association study involves about a million (or
more) statistical tests. This leads to a multiple-testing problem: When performing many
statistical tests of the same type, some of these tests will incorrectly reject the null
hypothesis just by chance. It is therefore important to make this incorrect rejection
less likely. A simple approach is to reduce the signiﬁcance threshold for statistical tests
so that the p-value has to be even lower than the typical 5% threshold to reject the
null hypothesis. It is common to use the Bonferroni-correction12 to either reduce the
signiﬁcance threshold or to raise the p-value - which, in the end, leads to the same
analytical result. Because a GWAS has about a million statistical tests, the p-value is
either multiplied by one million or the signiﬁcance threshold is divided by the factor one
million and thus becomes
0.05× 1
1000000
= 5× 10−8
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which is commonly referred to as the genome-wide significance threshold13;14.
An important principle in science is ”correlation does not imply causation”. If a SNP
is correlated with a disease, that SNP might still be irrelevant for the disease, because it
is in high linkage disequilibrium with the actual causal SNP, i.e. the SNP is commonly
inherited together with the causal SNP11. It is therefore necessary to not only consider
the SNPs with the lowest disease-association p-value (lead SNPs) but also all SNPs that
are in high LD with this SNP (LD SNPs) when investigating the causes of a disease1.
Another common problem with genome-wide association studies are the estimation
of eﬀect sizes. A p-value does provide an answer to the question whether or not a SNP
(or any of its LD SNPS) does have an eﬀect on a disease. But the actual impact of
that SNP is hard to determine15. For the diseases that will be presented in section 1.3
many SNPs have very low eﬀect sizes, i.e. their presence does not have a huge impact
on the development of a disease. It is usually the combination of several SNPs and
environmental factors that causes the disease to actually develop1.
Genome-wide association studies are usually huge endeavours which nowadays have
complete research consortia behind them like the International IBD genetics consortium
(IIBDGC) and the International Multiple Sclerosis Genetics Consortium 16 (IMSGC).
Furthermore, there are archival websites like the GWAS catalogue17 that provide access
to the results of past GWA studies and also make it possible to conduct meta-GWAS
studies7 with even greater sample sizes than before to increase statistical power.
Finally there is the challenge of interpreting the results of a GWA study. SNPs that
lie in coding regions with non-synonymous base-exchanges are comparatively easy to
understand. But many times SNPs lie in intronic regions or in intergenic regions. In the
latter case it is especially diﬃcult to assess which genes are aﬀected by a SNP.
In any case, genome-wide association studies provide a basis for further analysis to
understand phenotypes and especially diseases.
1.2. Inflammation
Humans and other organisms have immune systems to defend themselves against
pathogens. The immune system in humans consists of many diﬀerent cells that all
contribute to the defense against invaders18.
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However, the immune system has a diﬃcult task to perform: It should not attack the
tissue of the individual that it is supposed to protect18. Furthermore, humans live in
symbiotic relationships with microorganisms19. The immune system should not attack
or react aggressively towards these symbionts which live in speciﬁc areas of the human
body.
There is a class of diseases that are called chronic inﬂammatory diseases. In these
diseases the immune system overreacts and induces inﬂammation in disease-speciﬁc parts
of the body. These diseases are chronic and patients suﬀer from lifelong impairments.
Inﬂammation is a process that protects humans from tissue-invading microbes18.
It usually occurs after wounding when microbes enter the wound and immune cells
encounter these microbes. Inﬂammation leads to accumulation of leukocytes, plasma
proteins and ﬂuid derived from blood at the site of inﬂammation18 to ﬁght the invaders.
However, inﬂammation also comes with side-eﬀects that are problematic for the inﬂamed
tissue: Swelling, pain, redness, heat and loss of function20. Especially when inﬂammation
becomes chronic, tissue damage occurs18.
Inﬂammation can be regulated by diﬀerent diﬀerent immune cell types. Macrophages
can be pro- and anti-inﬂammatory, depending on the conditions21. Monocytes are usually
pro-inﬂammatory21. Regulatory T-cells are major regulators that prevent inadequate
immune responses22. Regulatory B-cells are a small subpopulation of B-cells that are
involved in the downregulation of inﬂammatory processes22.
Macrophages and Monocytes are part of the innate immune system while the regulatory
T- and B-cells are part of the adaptive immune system18. After resolution of inﬂammation
both types of immune cells aggregate in the tissue and reside there for weeks, so that
they can directly attack pathogens and cause inﬂammation if the same tissue is being
invaded again20.
1.3. Complex Diseases
The previous section explained the usefulness but also the harmfulness of inﬂammation.
It is therefore important to understand under which conditions inﬂammation gets out of
control. Based on this understanding it might be possible to develop cures for various
diseases.
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Understanding inﬂammatory diseases has turned out to be diﬃcult. The primary
reason is that many factors play together and our current understanding of these interplays
is very limited on the biological level. In fact, even though we know many genetic factors
(SNPs) that correlate well with disease, we do not know what the actual biological
consequences of these factors are because most of them lie outside of coding regions.
However, many SNPs lie within potential expression quantitative trait loci (eQTL)s that
may regulate the expression of speciﬁc genes via cis- or trans-eﬀects23.
There are ﬁve diseases that are being analysed in this thesis: Crohn’s disease (CD),
ankylosing spondylitis (AS), psoriasis (PS), primary sclerosing cholangitis(PSC) and
ulcerative colitis (UC). Each of these diseases causes chronic inﬂammation in patients
and the etiology of these diseases is still unknown. Table 1.1 shows the aﬀected organs of
these diseases. The diseases CD and UC are the most frequent subtypes of inﬂammatory
bowel disease (IBD) which cause inﬂammation in gastrointestinal organs. Beyond the
inﬂammation itself, the symptoms experienced by the patients include the following:
Ankylosing Spondylitis: Limited motion of the lumbar spine, persistent lower-back
pain, limited chest expansion24
Crohn’s disease: Can vary by subtype. Possible symptoms include rectal bleeding,
diarrhea, abdominal cramping pain (associated with iron deﬁciency), fatigue, weight
loss and fever25
Psoriasis: Psoriasis means itching condition in Greek. The patients experience itchy
skin with red scaly plaques18.
Primary Sclerosing Cholangitis: Symptoms can include fatigue, abdominal pain, jaun-
dice and fever26
Ulcerative colitis: Rectal bleeding, diarrhea, abdominal cramping pain25
It has been shown that these diseases are very similar on the genetic level despite having
mostly diﬀerent aﬀected organs1 which is the reason why they are being investigated
together in this thesis. But it has also been observed that there is a high comorbidity
between these diseases26: Patients having one disease have a high chance of developing
another within a time frame of ﬁve years2.
In addition to the known genetic factors there are also the environmental factors which
play a role1. It has been statistically shown that smoking is risk-inducing for Crohn’s
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Disease Primary aﬀected (inﬂamed) organs
ankylosing spondylitis Axial skeleton (mainly spine)
Crohn’s disease Any part of the gastrointestinal
tract from mouth to anus
psoriasis Skin
primary sclerosing cholangitis Bile ducts
ulcerative colitis Colon and rectum
Table 1.1.: Inflamed Organs in different inflammatory diseases
disease while at the same time it has a protective eﬀect against ulcerative colitis27. It
is hypothesized that smoking impairs autophagy28 and autophagy appears to be an
important process in Crohn’s disease29.
There are probably more factors at play here that are related to the lifestyle of
advanced ”western” human societies. Determining these factors is still a future challenge.
In fact, the incidence rate of these diseases has risen in recent decades while at the same
time the incidence rates of infectious diseases have fallen due to better hygiene30.
These diseases are called complex diseases because a great number of known genetic
factors inﬂuence the probability of developing such a disease in addition to environmental
factors. Because these diseases have an inﬂammatory component, they are sometimes
categorized as autoimmune diseases31. It is not uncommon for autoimmune diseases to
be complex polygenetic traits with a major environmental component18.
There are also less complex forms of some of these diseases. There are monogenic
forms of IBD32 where a single gene or in some cases a few genes suﬃce to cause the disease.
These types of non-complex diseases are not investigated in this thesis. Furthermore,
these less complex forms are much rarer than their complex counterparts32. Most variants
in common complex diseases have only very low eﬀect sizes and these complex diseases
usually develop much later in life than their monogenic forms32.
In addition to genetic and environmental factors it has also been shown that epigenetic
factors play a role in inﬂammatory diseases33 making the diseases even more complex.
Neurological aspects also seem to play a role in the regulation of inﬂammation. The
vagus nerve has been shown to be involved in the regulation of inﬂammation and might
be a promising target for therapy34. However, it is unclear if it is involved in cause of
such diseases. But the relevance of the vagus nerve also reﬂects well on the concept of
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Human health is maintained through many control mechanisms in the body. For
some diseases to develop, several checkpoints have to break down23 which ﬁts well with
the observation that many loci appear to play a role in these diseases. But it is probably
a speciﬁc combination of variants in the genome that drive the development of diseases1.
The central actors in the cell are proteins. They physically interact with each other
to form functional modules or they chemically modify each other. Proteins are involved
in many metabolic, communicative and structural processes6. The interactions between
proteins are an important aspect of their function. Most proteins do not act in isolation
but require other proteins to fulﬁll their purposes38. This alone accounts for a lot of
complexity in biological systems because it is diﬃcult to analyse proteins in isolation.
Protein do not only interact with each other but also with many other molecules,
most notably DNA and histones. They can act as transcription factors for genes and
thereby establish a relationship with these genes on a conceptual level6. Proteins are also
responsible for chemical modiﬁcations of DNA and histones. Speciﬁcally, these proteins
add or remove methyl or acetyl groups from DNA or histones. These modiﬁcations are
maintained upon DNA duplication and can also be passed on to future generations6.
Another important class of molecules in the cell are RNA molecules. These include
mRNAs which serve as a template for the translation of proteins but also non-coding
RNAs like microRNAs that interfere with mRNAs and thereby prevent translation39.
Thus microRNAs can interact with genes or proteins by downregulating their mRNA.
There are also long non-coding RNAs (lncRNAs) which are deﬁned as RNAs that are at
least 200bp long. These perform various functions in the cell40, including neutralization
of microRNAs40.
Finally there is DNA which harbours the template sequences for RNAs (including
precursors of mRNA). The previously mentioned genetic variants are found in the
DNA. Every variant in the DNA may inﬂuence the sequence of a RNA or protein
molecule. In addition any variant in the DNA may inﬂuence the binding of proteins to
the DNA. Common classes of DNA-binding proteins are transcription factors which bind
to enhancers, silencer, insulator or promoter regions of a gene6. Furthermore, histones
also bind to DNA but this binding has to be sequence-agnostic in order to fully condense
DNA into chromosomes6.
To summarize: Proteins, various RNAs and DNA can interact with each other in
diﬀerent fashions. These interactions are required for normal biological function and they
might be disturbed in disease.
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There is a principle called guilt-by-association which means that if a given protein is
known to interact with another protein, then it is likely that both proteins participate
in the same or related cellular functions41. The same principle can also be applied to
disease-associated genes/proteins: If two proteins interact and one of them is known to
be associated with a disease, then the other protein is also a good candidate for being a
disease-associated protein42.
To handle this complexity on the scientiﬁc level it makes sense to gather all known
interactions into a virtual network that represents the overall mechanisms that are
relevant to a disease. This is not a new idea and many projects have used networks to
represent collections of biological interactions43;44;45;46.
A network bundles all known interactions together and has the potential to reveal how
the diﬀerent genetic factors act together to cause disease. It may be used to explain how
interaction chains and interaction subnetworks are disturbed in these complex diseases
and they may be used to select therapeutic targets.
1.5. Introduction to protein-protein interaction
networks
A network is a very versatile formalism. Networks can represent relationships between
entities. The type of entities and the type of relationships can be many diﬀerent things
and networks have been applied to various research areas47;46. But for our purposes
we will focus solely on protein-protein interaction (PPI) networks. Protein-Protein
interaction networks are not the only networks that are relevant in molecular biology but
they are the most widely used form of networks in the research area of the inﬂammatory
diseases discussed in this thesis48.
A network consists of nodes and edges. A node represents an entity. An edge is a
connection between nodes and represents a relationship between entities. In a protein-
protein interaction network every node is a protein and an edge between two nodes
signiﬁes that there is evidence that these two proteins physically interact with each other.
This evidence is usually experimental evidence but there are also predictive approaches
to derive unknown protein-protein interactions from text mining49 or other data sources.
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Protein-Protein networks exhibit the small world phenomenon: The distance between
any two nodes in a connected component is on average 6.8 steps apart46.
1.5.2. Centralities (importance of nodes in networks)
A common concept to determine the importance of nodes in the network is to determine
their centrality 46. There are diﬀerent types of centrality. To deﬁne these centrality
measures more formally, let G = (V,E) be a graph consisting of nodes v ∈ V and edges
e ∈ E connecting these nodes. All networks presented in this thesis are graphs.
Let A be the adjacency matrix which is deﬁned as
Aij =

 1 vi and vj are connected by an edge0 otherwise

 (1.1)
The simplest centrality measure is degree centrality which corresponds to the degree
of a node:
degree(vi) =
n∑
j=1
Aij (1.2)
All hub nodes have a high degree centrality.
Other centrality measures are betweeness centrality, closeness centrality and eigen-
vector centrality. A node has a high betweeness centrality when many shortest paths
between any pairs of nodes in the network goes through the node itself:
betweeness(vi) =
∑
s,t∈V
vi(s, t) (1.3)
Where
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vi(s, t) =

 1 if shortest path from vs to tt goes through vi0 otherwise


A node has a high closeness centrality if it is possible to reach most other nodes in
the network with only few steps:
closeness(vi) = n ·
(∑
j∈V
γij
)
−1
(1.4)
Where γij is the length of the shortest path between node vi and node vj
The Eigenvector centrality deﬁnes the importance of a node based on the importance
of the nodes connected to that node:
eigen(vi) =
1
ρ
∑
j∈Γ(i)
eigen(vj) =
1
ρ
n∑
j=1
Aij · eigen(vj) (1.5)
Where ρ is the largest eigenvalue of A and Γ(i) is the set of neighbours of node vi.
There are also other centrality measures50 46. But they have not been used in this
thesis.
1.5.3. Pathways and Modules
It should be noted that currently we do not have complete knowledge of all interactions
in cellular systems. Therefore any networks that we construct will likely be incomplete51.
In addition to this incompleteness there are many false-positive interactions in the
databases48 which increase the complexity of the in-silico networks. Another problem is
the lack of temporal and spatial resolution of these interactions so that it is often not
known under which conditions an interaction actually takes place48.
Introduction 16
When we construct networks the objective is rarely to get a complete picture of a
biological system, but rather an approximation that is good enough to get insight into
key aspects of biology.
But this incompleteness does not mean that there are only few interactions. When
constructing networks in an automated fashion the resulting networks tend to be very
big and complex. While some of the complexity does indeed reﬂect biological reality, it is
advisable to reduce the networks so that they ideally focus on a single functional concept
that can be analysed.
One such functional concept is a pathway. A set of diﬀerent pathway analysis methods
exist. They take diﬀerent views on what constitutes a pathway38 but in the end they
either consider a pathway to be a speciﬁc set of nodes and/or a speciﬁc set of interactions
that may have a known functional description. It has been reported that the results
obtained from pathway-based analyses diﬀer greatly between methods52;53.
Another similar concept is that of a submodule. Modules in networks are subnetworks
that consist of nodes that have been selected as a group by an algorithm48. One example
of an algorithm is implemented by the jActiveModules Cytoscape plugin which tries
to ﬁnd groups of connected nodes that have highly signiﬁcant gene-wise association
p-values54.
Jia et al. describe ﬁve diﬀerent dimensions of ﬁnding modules (subnetworks) in a
network48:
• Binary categories (disease-associated or not disease-associated) versus quantitative
(disease association score)
• Network topology oriented versus node weight oriented (”genetically oriented”), or
a combination of both
• Global versus local search in the network space (limiting the maximum number of
steps in a network algorithm)
• Prioritization of single genes versus ﬁnding a combination of several genes for further
analysis
• Direct versus indirect interactions. Indirect interactions take into account the
number of paths between two non-connected nodes. More paths between two nodes
might indicate a strong relationship.
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Depending on the available data some options may not be available but overall there
are many possible choices.
1.6. Enrichment of terms and tissues based on gene
lists
A common result of bioinformatics analyses are lists of genes. These genes might share
common characteristics like being associated with the same disease, being inside a network
module or being diﬀerentially expressed.
Given that there are about 20.000 genes in the human genome55, the genes on the list
may be unknown to the researcher. Enrichment tools provide an automated approach
to give an overview about what the genes on a list have in common and what kind of
biological phenomena they are involved in.
Enrichment tools make use of existing gene annotations like the Gene Ontology56;57
and the KEGG pathway database58;59. But they can make also use of gene expression
data to perform tissue enrichment51. These tools determine a background distribution
for every annotation to assess how likely it is for a random gene to have a speciﬁc
annotation60. If signiﬁcantly more genes from the input gene list are annotated with a
speciﬁc term than expected by chance, it is said that the gene list is enriched for that
term. The statistics behind these methods usually use a χ2 or hypergeometric test38.
Tools like DAVID use a slightly modiﬁed version of the Fisher’s exact test61.
Depending on the experimental setup, the gene list might be subject to biases, like
certain genes having a greater chance to end up on the list because the genotyping chip
has a special focus on certain genes. In such a case a speciﬁc background has to be
provided to the enrichment tool to take into account these biases.
1.7. Objectives of this Thesis
A great number of factors contribute to the etiology of the ﬁve inﬂammatory diseases
presented previously. This thesis investigates how the known genetic factors could
potentially work together to cause disease. For this, the genetic factors will be mapped
to genes that are potentially aﬀected by these SNPs. The genes and their products
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(proteins) will be mapped into reference networks to get a better understanding on what
is common and what is diﬀerent between these diseases and to potentially gain further
insights into mechanisms of these diseases.
While the idea to project GWAS results into networks is far from new48, the combi-
nation of these speciﬁc ﬁve diseases is a novelty. A variety of approaches will be tried to
create networks that aim to represent and investigate the biology behind these diseases.
Chapter 2.
Material & Methods
“But there’s no sense crying over every mistake. You just keep on trying
’til you run out of cake. And the science gets done. And you make a
neat gun for the people who are still alive.”
— Mad robot GLaDOS (Lyrics)
This thesis features the combination of many approaches and tools to go from GWAS
data to network submodules. Figure 2.1 provides a generalized overview which kind of
steps have been taken in this thesis. It does not provide details about the speciﬁc tools
because these diﬀer from section to section and many more combinations of tools within
this workﬂow are conceivable.
2.1. SNPs
The SNPs of ﬁve diﬀerent diseases have been investigated in this thesis: Crohn’s disease,
ankylosing spondylitis, psoriasis, primary sclerosing cholangitis and ulcerative colitis.
Diﬀerent parts of this thesis used diﬀerent approaches. The ﬁrst approach used VEGAS62
to map all known SNPs to genes. These SNPs included also SNPs with a high (non-
signiﬁcant) p-value, because VEGAS can combine non-signiﬁcant SNP p-values to
signiﬁcant gene-wise p-values. Therefore 130,215 SNPs (without MHC region: 124,489
SNPs) have been used together with their association p-values for each disease. The
relevant results can be found in section 3.1.
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Later analyses only worked with the lead SNPs instead of all SNPs. These lead SNPs
were taken from the paper by Ellinghaus et al.2 (Figure 2.2L). In total 210 of the 244
association signals had their lead variant within the 10kb boundary surrounding a gene2.
The list of SNPs contains only 16 coding variants: 14 missense , 1 frameshift and 1 splice
donor2.
It was previously observed that many genetic factors are shared among diseases7;10.
To get a clearer picture on the common disease association of each SNP, the subset-based
meta-analysis method9 has been used by Ellinghaus et al.2. The subset-based meta-
analysis works with a list of SNPs and association p-values from diﬀerent diseases for
each SNP. The method tries all combinations of diseases and calculates a p-value for
every combination for a speciﬁc SNP being associated with exactly this combination of
diseases. In the end the lowest p-value of all combinations is taken for further analysis
together with the set of diseases that formed the most signiﬁcant combination. Figure
2.2R shows to which extent the SNPs are shared among the diseases based on the result
of the subset-based meta-analysis (ignoring eﬀect directions).
In addition to the SNP p-values from the subset-based meta-analysis, the SNP p-values
from the ﬁve individual diseases were also taken into account.
Most SNPs used in this study were detected with the ”Immunochip” which is a
genotyping chip that focusses on immune system-related SNPs10 and allows cost-eﬀective
genotyping of many individuals. However, this chip also introduces a bias because it was
designed to detect immune system-related genetic signals and it might fail to capture
important signals from other parts of the genome. In total the Immunochip allows
genotyping of 37,377 LD-independent markers2 which represent 195,806 SNPs and 718
small insertion–deletions10.
Every SNP from Ellinghaus et al.2 has an odds ratio for every disease. Odds ratios
are calculated as follows63:
D+
D−
:
H+
H−
(2.1)
Where D denotes the number of people in the study population who have the disease
while H denotes the number of people in the study population that are healthy. The
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CPDB version number of nodes number of edges
29 (90% conﬁdence) 16,620 (9,533) 444,311 (80,422)
30 17,105 (6,815) 471,097 (52,647)
31 17,460 (9,732) 551,362 (81,736)
Table 2.1.: Sizes of interactomes in the protein-protein interaction network database Con-
sensusPathDB. The numbers in parenthesis are the number of nodes and edges
that are left when all edges are removed that have a confidence value less than
95 percent. In the case of version 29 the first row gives the number of nodes and
edges for a minimum confidence of 90 percent.
+ modiﬁer selects the number of people that carry a speciﬁc allele and the − modiﬁer
selects the number of people who do not carry the allele.
An odds ratio of greater 1 indicates risk while an odds ratio smaller than 1 indicates
protection. The odds ratios are calculated with the frequency of the minor allele in the
population.
2.2. Protein-Protein Interaction Reference Databases
There are diﬀerent protein-protein interaction databases that can be used for obtaining
interaction data to construct networks. There are also metadatabases that consolidate
these individual databases into a big dataset.
ConsensusPathDB
The ConsensusPathDB (CPDB) is a metadatabase of protein-protein interactions. It
consolidates 18 protein-protein interaction databases64;65.
To account for false positive interactions, the CPDB uses the IntScore algorithm66
which assesses the plausibility of an interaction based on three topology criteria and three
annotation criteria. Every interaction in the CPDB is annotated with a conﬁdence score
between zero and one. The results presented in section 3.1 rely on interactions with a
minimum conﬁdence of 90 percent while later sections work with a minimum conﬁdence
of 95 percent. Given that this work spanned several years, diﬀerent releases of the CPDB
were downloaded and used to construct networks. The corresponding sections in the
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results part mention the exact version that was used for a particular analysis. Table 2.1
lists the sizes of the diﬀerent reference networks.
iRefIndex
The iRefIndex database67 is another popular protein-protein interaction metadatabase
that consolidates the information from several other databases. One central aim of the
iRefIndex metadatabase is to establish uniﬁed identiﬁers for all interactions taken from
ten major PPI databases.
The iRefIndex database was used by the International Multiple Sclerosis Genetics
Consortium for their analysis procedure16. For this reason the iRefIndex database
(version 13.0) has also been used to test a reimplementation of that procedure.
2.3. Mapping of SNPs to Genes
Various approaches have been used to determine the genes/proteins that are aﬀected by
disease-associated SNPs. Simple approaches like taking the closest gene or taking the
closest genes within 0.1cM distance have been abandoned in favor of more sophisticated
approaches like VEGAS and DEPICT.
VEGAS
VEGAS is a popular68;69;16 tool for mapping SNP disease association p-values to gene
disease association p-values. VEGAS can be used as a web service but it can also be
installed locally. For this thesis VEGAS version 0.8.27 has been downloaded and used.
VEGAS takes a list of SNPs and a genomic reference (by default hg18) as input and
produces a table of genes with p-values as output. VEGAS combines SNPs that can
be assigned to the same gene and calculates a single p-value. This approach has the
advantage that when a SNP has several non-genome-wide signiﬁcantly associated SNPs,
the combination of these SNPs might be suﬃcient to calculate a signiﬁcant gene p-value.
The gold standard for assigning several SNPs to a gene is already implemented in the
PLINK software package70 based on permutations62. The disadvantage of this approach
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is the long computation time and VEGAS uses Monte Carlo simulations to get a heuristic
result instead. It uses a vector-based χ2 test with one degree of freedom where every
component of that vector represents one SNP and the test assesses the signiﬁcance of a
gene.
Additional changes had to be made for the VEGAS software to run with our data.
The details are explained in section C.2.
VEGAS has been used for this work (section 3.1) until DEPICT emerged as an
alternative.
DEPICT
Another approach to get from SNPs to genes is implemented by the DEPICT software
by Pers et al.51. DEPICT maps SNPs to genes by prioritising genes from every locus
based on how similar these genes are to other genes from other loci. The similarity of
these genes is based on the number of shared annotations and the similarity of expression
proﬁles. This method is based on the principle that truly associated genes should share
functional annotations71;45. Or in other words: The genes in a group of disease-related
genes are probably annotated with similar terms.
DEPICT combines geneset enrichment with mapping of SNPs to genes. To account for
the incompleteness of gene annotations, DEPICT extends existing genesets (sets of genes
with a common/shared annotation) by ﬁnding genes that have similar gene expression
patterns. With this method 14,461 reconstituted genesets were constructed that cover
the complete genome. These reconstituted genesets are precomputed. Furthermore,
DEPICT makes use of 37,427 microarrays to identify tissue/cell types to identify highly
expressed genes for speciﬁc tissues.
Direct collaboration with Tune Pers was undertaken to let DEPICT run with our
data using an Immunochip-speciﬁc background for the enrichment to avoid biases. Table
2.2 lists the notable options used in the jobﬁles when running DEPICT.
DEPICT uses the hg19 genome reference and accounts for multiple testing by calcu-
lating the false discovery rate for enrichment results. It was used with the 244 SNPs from
the cross-disease study. Several runs were made for disease-speciﬁc p-values and Subset-
based meta-analysis p-values. DEPICT uses plink2 internally to identify genome-wide
signiﬁcant loci.
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GWAS FILE SETTINGS
association_pvalue_cutoﬀ 1e-5
PLINK SETTINGS
genotype_data_plink_preﬁx [...]/ALL.chr_merged.phase3_shapeit2 ←֓
_mvncall_integrated ←֓
_v5.20130502.genotypes
DEPICT SETTINGS
step_write_plink_input yes
step_write_plink_output yes
step_run_plink yes
step_construct_depict_loci yes
step_depict_geneprio yes
step_depict_gsea yes
step_depict_tissueenrichment yes
MISC SETTINGS
collection_ﬁle ld0.5_collection_depict_150315.txt.gz
reconstituted_genesets_ﬁle GPL570-GPL96-GPL1261 ←֓
-GPL1355TermGeneZScores ←֓
-MGI_MF_CC_RT_IW_BP_KEGG_z_z.binary
max_top_genes_for_gene_set 10
nr_repititions 20
nr_permutations 500
hla_start_bp 25000000
hla_end_bp 35000000
Table 2.2.: Important options that were used when running DEPICT. The list of SNPs differed
between each run.
When running, DEPICT makes use of a precomputed gene-to-geneset matrix which
contains a probability for every gene to be part of a speciﬁc reconstituted geneset. This
matrix was created based on gene expression and existing gene annotations. To construct
this matrix, every existing geneset was taken and a common expression proﬁle of all
genes in that geneset were calculated. Then the expression proﬁle of every gene outside
of this geneset was correlated with this common expression proﬁle and the correlation
was used to give the gene a probability to be part of that geneset.
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The gene prioritisation (SNP mapping) works as follows: DEPICT tries to ﬁnd the
most likely combination of genes across all GWAS loci that are most similar to each
other. This similarity is deﬁned through the reconstituted genesets and the tissues where
genes share high expression.
GoShifter
A rather unconventional approach to map SNPs to genes was performed by using the tool
GoShifter72 with ENCODE transcription factor binding sites annotations (TFBS). The
ENCODE transcription factor binding sites were downloaded on the 8th of September
2015. The two annotation ﬁles used for the mapping were ENCFF029ZUJ.bigBed
(proximal TFBS) and ENCFF787QYS.bigBed (distal TFBS). The bigBed ﬁles were
converted to BED ﬁles by using the tool bigBedToBed73. All genomic coordinates
referred to genome build hg19.
The annotations for the transcription factor binding sites contain the transcription
factors that bind to a genomic region and which might exhibit a diﬀerent binding aﬃnity
if a SNP lies within the binding region. It would have been helpful if the annotations
also included the genes that are regulated by the binding regions but this information
was not available in this context. However, in hindsight it is probably possible to at
least map proximal TFBS regions to the regulated genes. Thus this mapping is indirect:
A mapping to the potential regulator is performed but the regulated gene itself is not
known.
Transcription factor binding sites are especially interesting because they might act as
expression quantitative trait loci (eQTLs). A diﬀerent binding aﬃnity of a transcription
factor might directly aﬀect the transcription and therefore the expression levels of a
gene74.
GoShifter works by taking lead SNPs and determines the region in LD around each
lead SNP. All annotations in that region are overlaid with all LD SNPs and the number
of overlaps is determined as a base value. Then the coordinates of all annotations are
shifted by a random amount with wrapping around at the boundaries of the linkage region
to preserve local genomic characteristics72. After every shift the number of overlaps is
recorded. At the end a distribution of overlap counts is compared to the base value to
assess the probability of the real LD SNPs overlapping these annotations by chance.
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GoShifter also provides a stratiﬁed test to test dependence of diﬀerent annotations
against each other. This test works by moving all annotations that should be tested
directly adjacent to each other in a linkage block and then the shifting of the other
annotation type is performed as normal. Next a background distribution is determined
for the number of times a SNP overlaps both annotations versus a SNP overlapping only
the of the primary (shifting) annotation.
Because GoShifter does not report the original overlapping annotations when assessing
the signiﬁcance of an overlap, further backmapping had to be done by using the SNP
coordinates from the 1000 genomes project and the locations of the ENCODE TFBSs.
For every detected overlap the transcription factors were determined and used in later
analyses.
The risk status of every SNP was taken from supplementary table 3 of the paper by
Ellinghaus et al.2. Depending on the SNPs that are linked to a single gene, that gene
was assigned one of the following risk statuses:
Protective: Gene is only linked to protective variants
Risk: Gene is only linked to risk variants
Both: Gene is linked to risk and protective variants
None: Gene has no SNPs associated with the currently considered disease
Each of these classes was assigned for each of the ﬁve diseases.
2.4. ID mapping
Because diﬀerent analysis steps/tools use diﬀerent types of IDs, a mapping between
diﬀerent ID types was required for several procedures. The most frequent conversions
were needed from HGNC gene names to UniProt IDs. HGNC Gene names are used by
VEGAS and DEPICT and UniProt IDs are used by the ConsensusPathDB. The DAVID
webtool accepts a variety of ID types but for this thesis UniProt IDs were supplied.
ID mapping data was downloaded from genenames.org (using BioMart) and UniProt.
org (using the FTP server) and custom scripts were written in Python to map IDs from
one type to another. Sometimes ID mapping was also performed within Cytoscape by
importing mapping tables and matching with existing node IDs.
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2.5. Network handling
2.5.1. Cytoscape
Cytoscape is a tool to work with digital networks with a special focus on networks
in molecular biology75. Cytoscape is a graphical application and supports various
visualization, exploration, analysis and processing methods for networks. Throughout
this work Cytoscape versions 3.0 to 3.3 have been used.
Cytoscape also can make use of many plugins provided by the network research
community. One plugin used in this thesis is jActiveModules54. This plugin was
originally developed to ﬁnd submodules in gene expression networks. To determine these
submodules, the user has to provide gene-wise p-values and jActiveModules transforms
these p-values into z-scores (zi) for every gene-node i using the inverse cumulative normal
distribution. To calculate a score ZA for a subnetwork with a given set of k nodes, the
following formula is used:
ZA =
1√
k
∑
i∈A
zi (2.2)
And to calibrate this score against the background distribution the following formula
is used:
SA =
ZA − µk
σk
(2.3)
Where µk and σk are the mean and standard deviation of randomly sampled networks
respectively.
Because ﬁnding the best submodule is NP-hard, jActiveModules uses a simulated
annealing heuristic to ﬁnd good submodules. During the search every node is either
marked as active or inactive. Initially, every node has a chance of 50% to be part of
the active set. The search is performed by going through N iterations (for a given
N). At each iteration one node is picked randomly and its state is toggled (active or
inactive). Then the scores of every connected component consisting only of active nodes
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is calculated (with equation 2.3). The maximum score is recorded and compared with
the maximum score from the previous iteration. If the new score is higher, the node
stays toggled. Otherwise is stays toggled with the following probability:
exp(si − si−1/Ti) (2.4)
Where si, si−1 are the highest module scores in iterations i, i− 1 respectively and Ti
is the temperature value from the simulated annealing at iteration i.
After the N iterations the highest score and the corresponding connected component
is returned. This process can be repeated to ﬁnd several submodules.
Gene-wise overlap between diseases
To determine subnetworks that are speciﬁc to single diseases or speciﬁc subsets of diseases,
every node in the CPDB reference network (version 29) was annotated with VEGAS
gene-wise p-values. A Cytoscape plugin was written to annotate every node with the
number of signiﬁcant disease associations and to annotate each node with the diseases
themselves. Then the network was simpliﬁed by removing edges that had nodes for which
the diseases of these nodes contradicted each other.
Formally ”contradiction” can be expressed as follows: Let e be an edge connecting
two nodes n1, n2. Let d(n1), d(n2) be the sets of diseases associated with these nodes
respectively, then edge e is kept in the network if the following relationship is true:
d(n1) ⊆ d(n2) ∨ d(n1) ⊇ d(n2) (2.5)
That is, the diseases of one node have to be a superset of the diseases of another node
to ensure that only nodes are connected that could form a disease-speciﬁc subnetwork.
The nodes were then ﬁltered into diﬀerent categories by the number of diseases that
are associated with every node to form disease-subset-speciﬁc subnetworks.
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Geneset-based networks
The tool DEPICT was used to determine the most consistent sets of genes based on the
list of 244 cross-disease SNPs (See section 2.3 for details). DEPICT was run with each
disease-speciﬁc list of SNPs together with their p-values to determine the disease-speciﬁc
p-values. In addition, DEPICT was run with the list of SNPs with the SBM p-values.
The protein-protein interactions from the ConsensusPathDB version 30 were ﬁltered
to have a minimum conﬁdence value of 95% and the genes from DEPICT were mapped
into the network using Cytoscape. In addition, the genes from the paper ”Genetic insights
into common pathways and complex relationships among immune-mediated diseases” 10
were mapped into the network to see how well DEPICT was able to determine already
known disease genes.
For every node the associated diseases were determined and each node was annotated
with a stripe chart using the Enhanced Graphics Cytoscape plugin76. The resulting
network was laid out manually for better visual inspection.
REST-based scripting
As an easier alternative to writing plugins, Cytoscape 3 originally had JavaScript-based
scripting support which was also used to automate some parts of this work. This scripting
interface was deprecated in later versions of Cytoscape 3 because of incompatibilities
with the OSGi classloader which is a fundamental component of Cytoscape 3.
Keino et al. created the CyREST plugin for Cytoscape which exposes a REST
interface to the most common basic actions that would normally be performed with a
script77. With the help of this plugin a wrapper of the REST interface was written in
Clojure78. This made it possible to remote-control many parts of Cytoscape and also to
automate many tasks used to create the results in section 3.2 by writing regular Clojure
code instead of using raw REST calls.
The code is located in the supplementary folder cyREST-clojure_scripts.
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2.5.2. Effect directions of SNPs on the network level
While Cytoscape provided many convenient facilities to work with networks, it had
one fundamental ﬂaw: As a graphical application it is not possible to create a reliable
data processing pipeline from start to ﬁnish. Furthermore, Cytoscape provides no good
mechanisms to document the individual transformation and processing steps so that it is
easier later on to understand what was done and to automatically redo these steps.
The networkx python library (version 1.11) provides many facilities to work with
networks and is fully scriptable79. The Jupyter notebook (version 4.1.0) provides an
infrastructure to write code in many diﬀerent programming languages while at the same
time providing an easy way to write the rationale for every piece of code directly next to
it80. The Jupyter notebook improves on methods like knitR and Sweave by not requiring
a recompilation of the whole document when a change is made or when a new piece of
code or text is added.
The Jupyter notebook was used together with networkx to investigate how the eﬀect
directions of SNPs might play out on the network level (see section 3.3 for results).
The networks were created by using the ConsensusPathDB version 31 with interactions
that had at least a conﬁdence value of 95% which resulted in a global network of 9,732
nodes and 81,736 edges.
The disease genes and their risk status were taken from the procedure described in
section 2.3. They were mapped into the network and diﬀerent centrality measures and
assortativity values were calculated using the built-in functionality of networkx.
2.5.3. Network randomization
In order to assess how similar the networks are to random networks, random networks
have been generated with diﬀerent approaches. It is possible to generate random networks
based on picking random nodes or picking random edges while maintaining the overall
number of nodes and/or edges to keep the networks comparable. After generating the
random networks, a distribution over the metrics of the random networks is generated
and it is investigated in which quantile the metrics of the real network(s) lie. If they are
less than the 2.5% quantile or more than 97.5% quantile, they are signiﬁcantly diﬀerent
from random networks.
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To follow the example of the IMSGC, random networks were generated by randomly
sampling nodes and comparing the size of the largest connected component (nodes and
edges) of the real disease networks with the random networks. This randomization
and test procedure was written in D81 and 10,000 random networks were generated
for each of the ﬁve diseases. The randomization tests were done based on both, the
ConsensusPathDB (version 29) and the iRefIndex database version 13.
Edge randomisation is more meaningful than node randomization, because biological
networks tend to follow a power law which means that they contain only a few nodes of
very high degree. These nodes have a great inﬂuence on the connectivity of networks.
Randomly picking nodes will likely lead to an underrepresentation of these high-degree
nodes and it is therefore preferable to use edge randomisation which ensures that every
node maintains its degree, but the edges themselves point to other nodes.
Formally this procedure can be described as follows:
Let G = (V,E) be a graph where V is the list of nodes and E is the list of edges.
Each edge ei = (si, ti) has a source si and a target node ti. To randomise the edges, two
lists are generated:
S = (si | i ∈ 1, . . . , |E|) (2.6)
T = (ti | i ∈ 1, . . . , |E|) (2.7)
Where S is the list of source nodes and T is the list of target nodes. Based on T
a new list T ′ is generated by shuﬄing the entries in T and then a new list of edges is
generated:
E ′ = ((Si, T
′
i ) | i ∈ 1, . . . , |E|, si 6= ti, ∄i, j : E ′i = E ′j ∧ i 6= j) (2.8)
The edge randomisation was implemented in Python. If an edge was randomly
generated that did not fulﬁll the conditions in equation 2.8, it was attempted to ﬁnd a
replacement edge that fulﬁlls the conditions. Most of the time this was possible but in
general |E| ≈ |E ′| is only an approximation (observed worst case: Out of 1546 edges, 9
edges had to be dropped).
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Ten thousand randomizations were performed for the disease networks to assess their
dissimilarity to random networks based on the ConsensusPathDB reference network. The
sizes of the greatest connected components of each random and non-random network
were determined and the position of every real network within the distribution of random
networks was checked for signiﬁcance.
2.6. Term- and Tissue-Enrichment
DAVID
DAVID is a web-based enrichment tool. It is possible to upload lists of genes and test
these lists for enriched annotations. DAVID provides annotations from nine diﬀerent
backend databases61.
Throughout this work DAVID was used with the default annotations which also
included Gene Ontology terms and KEGG pathways. To perform the enrichment analyses,
the tool ”functional annotation clustering” was used to obtain clusters of enriched terms.
DAVID uses a slightly modiﬁed Fisher’s exact test (called EASE score). In this test
the number of genes from the input list that are within a geneset (or pathway) is reduced
by one before performing the normal Fisher’s exact test calculations.
DAVID calculates a p-value and a Benjamini-Hochberg-corrected p-value for every
enriched term. It also clusters enriched terms together when there there is a large number
of genes that share several terms. These clusters often have a common theme (like
immune-system processes). Each cluster gets a score and enrichment results are sorted
by this score.
DEPICT
DEPICT combines geneset enrichment with mapping of SNPs to genes. Please see section
2.3 for the details on how DEPICT performs SNP mapping.
DEPICT determines enriched tissues and enriched genesets for a given list of SNPs.
The enrichment results for tissues and for genesets were further categorized by how many
diseases share a tissue or geneset enrichment respectively. These enriched terms and
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tissues were sorted by their score and heatmaps were created with R using heatmap.2
from the gplots package.
GoShifter
GoShifter72 (Genomic Annotation Shifter) was primarily developed by Trynka et al. to
test whether a set of SNP overlaps with a set of genomic annotations and whether this
overlap is not by chance. To preserve local genomic structures, GoShifter randomly shifts
around annotated regions within linkage boundaries (r2 > 0.8) and determines all LD
SNPs for a given lead SNP within that region. The shifting is wrapped around at the
boundaries of the region to ensure that no annotations are lost.
GoShifter determines a null distribution to calculate the expected number of overlaps
under random conditions. The real number of overlaps is later compared to the distribu-
tion of random overlaps and a score is calculated that indicates how likely it is that the
real overlap is by chance. However, no clear cutoﬀ is given. In addition to the individual
scores for every lead SNP, GoShifter also calculates a global p-value for the combination
of the list of lead SNPs and the set of annotations to indicate if the annotations are likely
to be relevant for the list of SNPs.
GoShifter uses the hg19 genomic reference and also the SNP information from the 1000
genomes project under standard conditions. For this work the GoShifter development
version 0.2 was used (personal communication with Gosia Trynka).
KEGG
KEGG is the Kyoto Encyclopedia of Genes and Genomes58 59. It contains many curated
pathways but also oﬀers pathway enrichment and pathway search functionality on the
website. KEGG has been used to identify pathways when manually looking up the
functionality of various genes.
Chapter 3.
Results
“Now, these points of data make a beautiful line. And we’re out of beta.
We’re releasing on time! So I’m GLaD I got burned! Think of all the
things we learned! For the people who are still alive.”
— Mad robot GLaDOS (Lyrics)
There are many diﬀerent approaches to work with GWAS data to create networks48.
This is also shown in the upcoming sections where diﬀerent methods have been applied
to investigate inﬂammatory diseases.
The ﬁrst approach is based on an analysis workﬂow presented in the paper ”Network-
Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and
30,000 controls” 16. This workﬂow was reimplemented and adapted for the cross-disease
project.
The next network approach was based on the DEPICT software by Tune Pers et
al.51. DEPICT tries to ﬁnd plausible combinations of genes from GWAS data based on
preexisting gene annotation. The genes were then mapped into reference networks.
Lastly the direction of eﬀects of SNPs on the network level have been investigated to
understand better how protective SNPs may inﬂuence the susceptibility for disease.
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3.1. Common Network Modules Across Inflammatory
Diseases
Many SNPs used in this thesis are related to several diseases at once (for example
rs134079132, rs28123782). Network-based approaches can be used to investigate how
these multi-disease relations manifest themselves on the network level i.e. which modules
within a network are speciﬁc to single diseases and which modules are shared. This in turn
might provide better insights into the common mechanisms behind these inﬂammatory
diseases but also into the mechanisms that are speciﬁc to single diseases.
The International Multiple Sclerosis Genetics Consortium developed a workﬂow to
derive network submodules from GWAS data in multiple steps16. This workﬂow has
been adapted and reimplemented for this thesis, to work with our multi-disease SNP sets
from the ﬁve diseases.
3.1.1. SNP to Gene Mapping
VEGAS is a tool to determine gene-level p-values from SNP-level p-values. VEGAS was
run with 130,215 SNPs with disease-speciﬁc p-values for each disease. A total of 5,726
SNP are located in the MHC region and VEGAS was used with SNP lists containing
the MHC region as well as SNP lists without them. It should be noted that these lists
contain SNPs which are not all genome-wide signiﬁcantly associated. But VEGAS can
combine several non-signiﬁcant SNP p-values into a signiﬁcant p-value for a gene (see
methods).
Table 3.1 displays the number of genes VEGAS listed based on the p-values of the
SNPs of each individual disease. There are major diﬀerences between the number of
genes determined when MHC SNPs were used and when they were excluded (Table 3.2).
Some of the gene-wise p-values that VEGAS produced are equal to zero (Table 3.3)
which is a phenomenon that the authors of VEGAS describe to be due to ”computational
reasons”.
A comparison with the 1,443 IBD genes from Jostins et al.7 showed that 906 of the
5,827 genes detected by VEGAS are common between the two studies. When the MHC
region is left out, the overlap with the genes by Jostins et al. is 877 genes.
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No MHC With MHC
Disease signiﬁcant genes total genes signiﬁcant genes total genes
All 3,612 12,428 3,888 12,705
AS 2,201 12,420 2,465 12,686
CD 2,832 12,407 3,115 12,693
PS 1,488 12,410 1,706 12,675
PSC 1,527 12,408 1,789 12,674
UC 2,472 12,420 2,712 12,685
Table 3.1.: Number of genes reported by VEGAS with and without MHC region. The
significance threshold is five percent. The corresponding genes were then used for
further analysis. ”All” denotes the combination of SNPs from all five diseases.
Disease Common genes Additional genes without MHC Additional genes with MHC
All 2,841 771 1,047
AS 1,164 1,037 1,301
CD 2,218 614 897
PS 563 925 1,143
PSC 1,035 492 754
UC 2,343 129 369
Table 3.2.: Numbers of significant genes detected by VEGAS (significance threshold of 5%)
for different diseases. VEGAS was used with SNP lists lacking and containing
MHC region SNPs in different runs. The ”Common genes” are genes detected by
VEGAS with both lists. As indicated above the results from the non-MHC runs
differ from the with-MHC runs to a notable extent.
Disease Common genes Additional non-MHC genes Additional MHC genes
All 174 420 698
AS 21 48 295
CD 315 112 219
PS 30 42 189
PSC 14 48 309
UC 116 100 217
Table 3.3.: Counts of VEGAS gene-wise p-values that are exactly zero. VEGAS was run
with SNP lists containing and lacking the MHC region. The ”Common genes” are
genes detected by VEGAS with both lists. According to the paper by Liu et al.62,
VEGAS produces these p-values because of ”computational reasons”.
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Disease Number of nodes Number of edges
AS 1122 1279
with MHC 1234 1546
CD 1504 2463
with MHC 1616 2840
PS 753 751
with MHC 852 964
PSC 808 923
with MHC 923 912
UC 1295 2214
with MHC 1403 2564
Table 3.4.: Sizes of disease-specific subnetworks containing only nodes that have been identified
by VEGAS as significantly associated (significance threshold 5%). The protein-
protein interactions themselves have been taken from the ConsensusPathDB (ver-
sion 29) and were filtered to have at least a confidence value of 90%. Each of these
subnetworks had one large connected component, some very small independent
subnetworks and many unconnected nodes (not shown).
The signiﬁcantly associated genes from all runs were then used for further analysis.
3.1.2. Disease networks
In order to see how the genes that were detected by VEGAS interact with each other,
the protein-protein interaction reference ConsensusPathDB64 65 version 29 has been
downloaded and ﬁltered down to only contain those interactions that have a conﬁdence
value of at least 90 percent. The remaining interactions have been combined into a
network of 9,533 nodes and 80,422 edges inside Cytoscape.
The genes from VEGAS were mapped into the network. For every disease and every
gene and each of the two MHC conﬁgurations it was determined if the VEGAS p-value
was below 5% and if that was the case, the gene was included in the disease-speciﬁc
subnetwork. Table 3.4 lists the sizes of the subnetworks.
Further analyses also took into account so-called linker genes which are genes/proteins
that have a known interaction with a disease gene but are themselves not known to
be associated with the disease. When including linker genes the networks become a
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Figure 3.1.: Network of all disease genes with their direct neighbours which themselves might
not be known to be associated with any of the five diseases. The network consists
of 8,105 nodes and 52,523 edges. The network itself is very large and hard
to investigate visually. In network science such networks are called ”hairballs”
because of their visual complexity82.
considerably larger (see Figure 3.1) and an analysis becomes more complex. In principle
linker genes may actually turn out to be disease genes83;84. They will be taken into
account in section 3.2.6 but for this part they will not be shown because the data is too
noisy.
Permutation tests
In accordance to the procedure from the paper by the Multiple Sclerosis Genetics
Consortium, distributions of random networks were generated by randomly sampling
nd,M proteins from the ConsensusPathDB where nd,M is equal to the number of signiﬁcant
genes in disease d with MHC-conﬁguration M (including MHC genes or leaving them
out). For each of these randomly sampled proteins a subnetwork was created and the
number of edges and the number of nodes in the largest connected component was
determined for comparison with the real subnetworks. This was done to see if the real
networks are diﬀerent from randomly generated networks. For every distribution 10,000
random samples were chosen.
Figures 3.2 and 3.3 depict the number of edges and the number of nodes in the largest
connected components in diﬀerent quantiles compared to the real number of edges and
nodes. It can be observed that the subnetworks of the real networks were signiﬁcantly
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diﬀerent from all random subnetworks (greater number of nodes and edges than all
random subnetworks).
The IMSGC did not use the ConsensusPathDB for their workﬂow. They used the
iRefIndex67 protein-protein meta-database. For comparison the same permutation tests
were done with the iRefIndex meta-database and the real networks were signiﬁcantly
diﬀerent from the random networks.
Node randomization has the fundamental problem that it does not reﬂect the distri-
bution of node degrees well. Biological networks are often scale-free and therefore the
degrees are far from evenly distributed (see section 1.5.1). When randomizing networks
it is much better to randomize the edges and maintain the degree of every node.
An additional edge randomization (10,000 permutations) for every disease subnetwork
with each MHC conﬁguration was done. With one exception, the largest connected
component of the random networks was always larger than the largest connected compo-
nent of the corresponding real network. The only exception was the PS network. But
this network still had a smaller largest connected component than 99% of all random
PS-networks and thus the real networks are all signiﬁcantly diﬀerent from the random
networks. Table 3.5 contains the percentiles of the random networks.
3.1.3. Protein-interaction-network–based pathway analysis
(PINBPA)
After the conﬁrmation of the non-randomness of the disease subnetworks, each of these
subnetworks had to be investigated more closely. Given the size of the subnetworks
(Table 3.4), it is hardly feasible to understand them by visual inspection. Thus it makes
sense to ﬁnd submodules of smaller size that can be characterized more closely.
The Cytoscape plugin jActiveModules54 was used with every disease subnetwork and
up to 20 submodules were generated. Table 3.6 lists the scores of the best modules and
ﬁgures 3.4 to 3.14 show the submodules themselves.
To get an idea about what each module could represent on the biological level, every
module was tested for term enrichment with the DAVID webtool61. The ﬁgures 3.4 to
3.14 summarize the enrichment results in their caption texts.
Results 41
Disease MHC Real network 0% 25% 50% 75% 100%
AS no 575 590 614 618 623 641
AS yes 671 685 712 717 721 739
CD no 913 925 944 949 952 966
CD yes 1009 1028 1050 1055 1059 1073
PS no 346 341 362 365 369 379
PS yes 420 424 449 453 456 470
PSC no 352 366 391 397 402 426
PSC yes 466 472 502 507 512 530
UC no 785 795 815 819 823 836
UC yes 868 883 907 911 915 927
Table 3.5.: Percentiles of the random networks obtained from edge endpoint randomisation.
All numbers correspond to the number of nodes in the largest connected component
(LCC) in each network. With the exception of PS (without MHC) all non-random
networks have a smaller LCC than all random networks. But more than 99 percent
of the PS-derived random networks have a LCC greater than the non-random PS
network and therefore all non-random networks are indeed non-random.
Module jActiveModules score Figure
AS module 1 7.16 3.4
CD module 1 7.89 3.5
PS module 1 5.48 3.6
PS module 2 5.36 3.7
PSC module 1 5.52 3.8
UC module 1 6.63 3.9
All ﬁve diseases module 1 10.44 none (too big)
AS module 1 with MHC 8.67 3.10
CD module 1 with MHC 8.80 3.11
PS module 1 with MHC 7.56 3.12
PSC module 1 with MHC 7.71 3.13
UC module 1 with MHC 6.52 3.14
Table 3.6.: Scores of the best modules produced by the jActiveModules Cytoscape plugin.
According to personal communications with the IMSGC, a module score of at least
3.0 was considered to be the threshold for a sound module.

Results 43
SH2B1_HUMAN
I12R2_HUMAN
NFKB1_HUMAN
JAK2_HUMAN HSP76_HUMAN
ACTA_HUMAN
AT2A1_HUMAN
ERN1_HUMAN
MYH10_HUMAN
TNR1A_HUMAN
IMB1_HUMAN
TRADD_HUMAN SCNNA_HUMANUBP2_HUMAN
TANK_HUMAN
IL23R_HUMAN
TNR6_HUMAN
CFTR_HUMAN
PTN11_HUMAN
CCR2_HUMANCD19_HUMAN
UB2L3_HUMAN
ZAP70_HUMAN
SH2B3_HUMAN
VAV_HUMAN
TYK2_HUMAN
Figure 3.4.: Best jActiveModule for ankylosing spondylitis with a score of 7.16 – The module
consists of 26 nodes and 29 edges. Major enrichment terms are SHC2 domain
and intracellular signaling cascade. SH2 is known to be a common element of
intracellular signaling cascades and the human genes ZAP70, TKY2, PTN11,
SH2B1, JAK2, SH2B3 and VAV are annotated with this term. Further terms
include ATP binding (10 of 26 nodes) and various binding with other biochemical
molecules. Cell death and apoptosis is another prominent theme of this module.
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Figure 3.5.: Best jActiveModule for Crohn’s disease with a score of 7.89 – The module consists
of 126 nodes and 293 edges. The network is too large to show it in full detail. The
network is enriched for Jak-Stat signaling and SH2 domains. It appears to play
a role in the regulation of the I-κB kinase cascade. 33 out of the 126 nodes are
annotated with ATP-binding and regulation of apoptosis/cell death. Regulation
of cytokine production is related to 18 genes. T-cell activation is relevant for
twelve genes. More terms include response to wounding, inflammation, response
to bacterium (NOD2 and twelve others).
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Figure 3.6.: Best jActiveModule for psoriasis with a score of 5.48. No enriched terms were
found which is probably due to the small size of this module. However, it is known
that these two molecules interact with each other to form the IL23 interleukin85.
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Figure 3.7.: Second-best jActiveModule for psoriasis with a score of 5.36 – This module
consists of 32 nodes and 46 edges. This module is enriched for transcriptional
regulation and DNA binding. The Jak-Stat pathway and the SH2 domain are a
common annotation term. 6 genes are annotated with T-cell activation: STA5B,
IL7RA, ICAM1, IL23A, INAR1, IL12B.
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Figure 3.8.: Best jActiveModule for primary sclerosing cholangitis with a score of 5.52 –
This module consists of 23 nodes and 31 edges. The genes in this module are
annotated with Jak-Stat signaling, SH2 domain, regulation of growth, regulation
of inflammatory response, positive regulation of the differentiation of various
immune cells.
GNAI2_HUMAN
NFKB1_HUMAN
SMCE1_HUMAN
NOTC1_HUMAN UB2L3_HUMAN
REL_HUMAN
AAKB1_HUMANITCH_HUMAN
PLCG2_HUMAN
SOCS1_HUMAN
LIME1_HUMAN
I12R2_HUMANERBB2_HUMAN
LPXN_HUMAN
FCG2A_HUMAN
STA5B_HUMAN
PTN2_HUMANRON_HUMAN
STAT3_HUMAN
IL23R_HUMAN
JAK2_HUMAN
SH2B1_HUMAN
KS6A4_HUMAN
SPN90_HUMAN MK03_HUMAN
MAPK2_HUMAN HNF4A_HUMAN
CREM_HUMAN
UB2J2_HUMAN
CUL2_HUMAN
IRF1_HUMAN
SYQ_HUMAN IRF5_HUMAN
SGF29_HUMAN
KAT2A_HUMAN
CD19_HUMAN
FCG3A_HUMAN
FAK2_HUMAN
LAT_HUMAN
ITAL_HUMAN
PTPRC_HUMAN
Figure 3.9.: Best jActiveModule for ulcerative colitis with a score of 6.63 – This module consists
of 41 nodes and 55 edges. Annotations for this module include enzyme/protein-
kinase binding, Jak-Stat signaling pathway, response to wounding, defense re-
sponse, inflammatory response, SH2 domain, response to organic substance (ten
nodes).
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Figure 3.10.: Best jActiveModule for ankylosing spondylitis with MHC with a score of 8.67
– This module consists of 42 nodes and 61 edges. This module is annotated
with chromatin, methylation, acetylation, various histones and macromolecular
complex assembly (16 genes, but not all of them are involved in the same
complex formations. Examples: Histone assembly, death-inducing signaling
complex (DISC), MHC class 1 folding). Further terms include immune response
and the MAPK signaling pathway.
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Figure 3.11.: Best jActiveModule for Crohn’s disease with MHC with a score of 8.08 – This
module consists of 125 nodes and 317 edges and is too large to show it in full
detail. Enrichment terms include response to molecule of bacterial origin and
response to lipopolysaccharide. The regulation of protein kinase cascades and
cell communication/signal transduction are further terms as well as apoptosis
and cell death. 35 of the genes are annotated with regulation of cell proliferation
and 34 are annotated with regulation of cell death (overlap: 22 genes). Another
theme are transcriptional regulation, Jak-Stat signaling, the SH2 domain and
immune cell regulation.
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Figure 3.12.: Best jActiveModule for psoriasis with MHC with a score of 7.56 – This module
consists of eight nodes and eight edges. The DAVID webtool had difficulties
mapping five of the eight IDs. These five IDs belong to HLA-related (MHC) genes.
The remaining three genes were annotated with terms like MHC protein complex,
allograft rejection, Type 1 diabetes mellitus, immune response, glycoprotein,
transmembrane.
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Figure 3.13.: Best jActiveModule for primary sclerosing cholangitis with MHC with a score
of 7.71 – This module consists of 20 nodes and 30 edges. Notable enriched
terms include antigen processing and presentation, various MHC terms, immune
response, host-virus interaction, membrane and transport, TAP/1/2 binding.
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Figure 3.14.: Best jActiveModule for ulcerative colitis with MHC with a score of 6.52 – This
module consists of 7 nodes and 7 edges. The second-best module (not shown)
consists of 101 nodes and 182 edges. The DAVID enrichment results included
the Jak-Stat pathway, SH2 domain, response to organic substance, response to
ethanol (STA5B, FAK2, STAT3, corrected p-value 20%).
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Figure 3.15.: Color legend for nodes that are associated with different numbers of diseases.
PINBPA
The workﬂow in the paper ”Network-Based Multiple Sclerosis Pathway Analysis with
GWAS Data from 15,000 Cases and 30,000 Controls” requires many individual steps that
need to be combined together. Wang et al. wrote the PINBPA plugin for Cytoscape
to encapsulate most of this workﬂow as a Cytoscape plugin86. Repeating these steps
with the help of this plugin yielded subnetworks that were considerably larger than the
networks obtained with jActiveModules.
A central problem with the PINBPA plugin is that it is designed to follow the
procedures in the IMSGC paper16 very closely and does not oﬀer adaptation to diﬀerent
workﬂows, like analyzing ﬁve diseases at once. Because the source code is not available
(even not on request), it was not possible to adapt the plugin to my own needs and
therefore the analysis with PINBPA has been discontinued.
3.1.4. Gene-wise Overlap Between Diseases in Networks
In order to better understand which parts of a network are relevant for a subset of the
diseases and which parts are shared by all or most of the diseases, edges were pruned so
that only those nodes were connected that had a consistent set of diseases associated
with them (see section 2.5.1 for details).
After pruning the network (by removing 162 edges and 1135 singleton nodes), 351
nodes and 523 edges remain. Figure 3.16 shows that about one quarter of the genes
are associated with all ﬁve diseases while another quarter is associated with exactly one
disease. About one sixth of the nodes are associated with either exactly four, three or
two diseases.
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Figure 3.16.: Interactions between proteins that are associated with different numbers of
diseases. In total the network consists of 351 nodes and 524 edges. Colors
correspond to the legend in figure 3.15. The edges have the color of the
connecting node that has the least diseases associated with it.
Number of diseases 5 4 3 2 1 Number of nodes
5 40 116 95 85 145 98
4 116 10 37 40 86 56
3 95 37 3 19 67 58
2 85 40 19 1 53 40
1 145 86 67 53 19 99
Table 3.7.: Symmetric matrix of the number of edges between nodes that have different
numbers of diseases associated with them. For every edge the relationship in
equation (2.5) holds true. In addition the number of genes that are associated
with a specific number of diseases is shown on the right. These numbers are based
on the network in figure 3.17.
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Figure 3.17.: Interactions between proteins that are associated with different numbers of
diseases. In total the network consists of 351 nodes and 524 edges. See table 3.7
for details on the number of edges between each cluster. Colors correspond to
the legend in figure 3.15. The edges have the color of the connecting node that
has the least diseases associated with it.
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Figure 3.18.: Nodes associated with all five diseases. The network consists of 98 nodes and
40 edges. Subnetwork A is enriched for Jak-Stat signaling. Subnetwork B is
enriched for cell cycle regulation. Subnetwork C is enriched for DNA binding
and histone modifications.
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Figure 3.19.: Nodes associated with exactly four diseases. The network consists of 55 nodes
and ten edges. The connected component consisting of LMNA, SMAD3, MED24
and THRA are associated with AS, CD, PS, and UC. ICAM1 and IL2RA are not
associated with UC. ERAP1 and ERAP2 are not associated with CD. CXCR2
and CXCR1 are not associated with PS. RL18 and RL5 are not associated with
UC. The STATs are not associated with AS.
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Figure 3.20.: Nodes associated with exactly three diseases. The network consists of 58 nodes
and three edges. UBE2D3 and NFKB1 are associated with AS, PSC and UC.
HSPA6 and TAB1 are associated with AS, CD and UC. IL4 and IL13 are
associated with CD, PS and UC.
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Figure 3.21.: Nodes associated with exactly two diseases. The network consists of 30 nodes
and one edge. BCAR1 and GELS are associated with CD and PSC.
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Figure 3.22.: Nodes associated with exactly one disease. The network consists of 99 nodes
and 19 edges. All nodes in the largest complex are associated with Crohn’s
disease. An enrichment analysis and a manual investigation of this complex did
not detect a common theme of these connected genes. The complex consisting
of ATP5H, ICT1 and CH60 is also associated with CD. CLEC2A and KLRF2
are associated with PSC. The following pairs of genes are all associated with AS:
HIP1R and HIP1, TNR6 and TNR1A, TEC and P85B, CO2A1 and MMP1.
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Disease Number of SNPs Number of FDR-signiﬁcant p-values
reconstituted geneset terms
All 5 244 1981 ≤ 1.12−3
CD 185 1730 ≤ 1.08−3
UC 164 1447 ≤ 1.53−3
AS 113 815 ≤ 8.50−4
PS 66 1006 ≤ 7.35−4
PSC 61 508 ≤ 2.88−4
Table 3.8.: Numbers of enriched genesets determined with DEPICT given different sets of
SNPs. In the case of ”All 5”, a combined SBM-based SNP p-value was used. A
geneset is a predefined set consisting of genes which are themselves similar or related
in some regard with each other. DEPICT uses its own reconstituted genesets
which have been created by extending existing genesets with further predicted
members. The FDR threshold is < 0.01. The p-value limits listed indicate the
highest p-values under this FDR threshold.
A closer investigation of the distribution of the edges (see Figure 3.17 and table 3.7)
showed that interactions between genes of equal diseases status are much rarer than
interactions between genes with diﬀerent diseases status. Nevertheless, the subnetworks
consisting of nodes with equal disease counts have been created (Figures 3.22 to 3.18)
and even though they are mostly unconnected, there are some interesting connected
components in them. For instance, ﬁgure 3.18A shows a component that has Jak-Stat
signaling-related genes as well as other signaling-related genes.
3.2. Geneset-based networks
A completely diﬀerent approach to obtain networks from GWAS data is based on the
tool DEPICT51. DEPICT tries to link lead SNPs to genes with the help of predeﬁned
genesets. See the section 2.3 for details on the method and the used parameters.
DEPICT was run with all 244 SNPs from the cross-disease dataset (SBM p-value)
but it was also run with all subsets of SNPs that are speciﬁc for each single disease.
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EGFR PPI subnetwork
increased B cell apoptosis
ATF1 PPI subnetwork
protein tyrosine kinase activity
BAD PPI subnetwork
positive regulation of production of molecular mediator of immune response
PAK2 PPI subnetwork
CD81 PPI subnetwork
INSR PPI subnetwork
BTF3 PPI subnetwork
poikilocytosis
USP15 PPI subnetwork
regulation of cellular response to stress
regulation of JUN kinase activity
TAB1 PPI subnetwork
JNK cascade
abnormal osteoblast differentiation
negative regulation of reproductive process
PLCE1 PPI subnetwork
stereocilium bundle
abnormal vasodilation
eukaryotic cell surface binding
NARS PPI subnetwork
TDRD3 PPI subnetwork
ENSG00000164605 PPI subnetwork
GCC2 PPI subnetwork
MRPS14 PPI subnetwork
QARS PPI subnetwork
CDS1 PPI subnetwork
increased circulating bilirubin level
IPO8 PPI subnetwork
diacylglycerol kinase activity
TOP2B PPI subnetwork
FHL1 PPI subnetwork
IARS PPI subnetwork
impaired embryo implantation
COPS2 PPI subnetwork
structure−specific DNA binding
SOD1 PPI subnetwork
abnormal megakaryocyte progenitor cell morphology
pallor
REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS
VWF PPI subnetwork
IKBKAP PPI subnetwork
MS4A5 PPI subnetwork
cholesterol transporter activity
FOLH1 PPI subnetwork
DAB2 PPI subnetwork
REACTOME_SIGNALING_BY_NOTCH
DENND1B
SPRED2
BACH2
USP25
SMAD3
RAVER1
TNFSF8
UBE2L3
BANK1
MAGI3
SPATA2
ICAM4
LCE2B
ZC3H12C
IL28RA
STX4
IL28RA
C1orf68
IFIH1
IFIH1
ENSG00000229191
FAM55A
EFNA1
CCNY
SNAPC4
ITLN1
ITLN1
IFIH1
KRTCAP2
SNAPC4
RNF123
CXCR2
SH2B3
BACH2
RNF123
NAA25
ICOSLG
C1orf93
NKX2−3
BSN
ICAM4
ICAM4
ACTA2
ITGB3
PPP2R3C
ITLN1
ITLN1
ACAD10
GPR35
DAG1
Figure 3.25.: Enriched genesets for every disease that are specific for a single disease (according
to DEPICT). The colors correspond to the legend in figure 3.24. The heatmap
cells are annotated with the gene that contributes the most to the enrichment
of the term in a disease.
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CSF1R PPI subnetwork
decreased plasma cell number
KEGG_PRION_DISEASES
CCR1 PPI subnetwork
KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS
PIK3R2 PPI subnetwork
abnormal physiological neovascularization
increased spleen germinal center number
antigen binding
ERBB2 PPI subnetwork
membrane raft
insulitis
increased long bone epiphyseal plate size
NCLN PPI subnetwork
abnormal mast cell morphology
regulation of JNK cascade
abnormal mammary gland development
TCF7L2 PPI subnetwork
S100A8 PPI subnetwork
regulation of stress−activated protein kinase signaling cascade
regulation of protein serine/threonine kinase activity
PIAS2 PPI subnetwork
abnormal branching of the mammary ductal tree
KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION
double−stranded DNA binding
regulation of T cell receptor signaling pathway
regulation of antigen receptor−mediated signaling pathway
AP1M1 PPI subnetwork
BCL2 PPI subnetwork
RPS27A PPI subnetwork
NCL PPI subnetwork
viral reproductive process
IKZF3 PPI subnetwork
HNRNPU PPI subnetwork
increased incidence of ionizing radiation−induced tumors
increased circulating alanine transaminase level
gastrointestinal hemorrhage
nuclear inner membrane
IRAK2 PPI subnetwork
regulation of interleukin−1 production
CLEC4M PPI subnetwork
CD2AP PPI subnetwork
abnormal cell physiology
decreased megakaryocyte cell number
abnormal fat pad morphology
CREM MUC19
GPR65 CCR6
GPR65 CCL2
CCRL2 CCL7
IRGM IRGM
HDAC7 ETS1
OSMR CCL7
LPXN CCR6
CCR5 FCGR2B
RPS6KA4 SMURF1
PTGER4 PTGER4
IFNG TLR4
ENSG00000253298 PDGFB
ITLN1 ITLN1
IL2 IL2
IL28RA RNASET2
NFKBIA STAT3
B3GNT2 SOX4
GCA CXCR1
ZNF646 RNASET2
IL28RA C5orf62
RNF114 STAT5B
HSD3B7 GRB7
TNFAIP3 LITAF
NKX2−3 RMI2
ENSG00000228037 ENSG00000228037
ENSG00000228037 ENSG00000228037
IL2 ENSG00000255479
GPBAR1 GPBAR1
NFKB1 UBE2L3
AAMP PPM1G
MAPKAPK5 TRMT112
HDAC7 DGKE
RHOA NCOA5
SPATA2 FAS
SULT1A2 GLYAT
APOBR APOBR
IL6R ENSG00000228037
ACAD10 ACAD10
FAM118A DNAJC27−AS1
ITLN1 ITLN1
ITGAL MUC19
ERN1 ENSG00000236263
IL1R1 ENSG00000197146
RNFT1 LNPEP
Figure 3.26.: Enriched genesets for every disease that are specific for exactly 2 diseases
(according to DEPICT). The colors correspond to the legend in figure 3.24. The
heatmap cells are annotated with the gene that contributes the most to the
enrichment of the term in a disease.
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negative regulation of sequence−specific DNA binding transcription factor activity
positive regulation vascular endothelial growth factor production
positive regulation of stress−activated protein kinase signaling cascade
BCL2L2 PPI subnetwork
positive regulation of monooxygenase activity
increased lymphoma incidence
decreased hemoglobin content
USP11 PPI subnetwork
positive regulation of protein complex assembly
lymph node development
prolonged estrous cycle
lipid storage
osteopetrosis
BID PPI subnetwork
COMMD1 PPI subnetwork
regulation of tissue remodeling
ICAM5 PPI subnetwork
regulation of fatty acid transport
ITGA4 PPI subnetwork
OPA1 PPI subnetwork
MRPL44 PPI subnetwork
receptor signaling protein serine/threonine kinase activity
REACTOME_PECAM1_INTERACTIONS
MYD88 PPI subnetwork
INPP5D PPI subnetwork
UBE2L6 PPI subnetwork
interferon−gamma−mediated signaling pathway
cellular response to interferon−gamma
response to interferon−gamma
myeloid leukocyte activation
thymus atrophy
abnormal leukocyte morphology
positive regulation of CD4−positive, alpha−beta T cell differentiation
positive regulation of CD4−positive, alpha−beta T cell activation
increased airway responsiveness
altered susceptibility to infection
increased susceptibility to infection
mixed cellular infiltration to dermis
increased susceptibility to autoimmune disorder
abnormal response to transplant
KIT PPI subnetwork
regulation of immunoglobulin production
abnormal immune system cell morphology
increased double−negative T cell number
RNF114 GPR35 ZGPAT
ZC3H12C GPR35 LACC1
LCE3D ENSG00000229191 ENSG00000229191
IFIH1 RIC8B PPP5C
IL23R ENSG00000257711 IL23R
RMI2 CD28 FEN1
ICAM4 RNF123 ICAM4
AAMP RABEP2 AAMP
NKX2−3 NKX2−3 NKX2−3
BSN−AS2 FAM55A CCR6
NFKBIA IL3 IL3
LINC00302 BSN−AS2 BSN−AS2
HSD3B7 APOBR APOBR
SOCS1 IFNG SP140
TNFAIP3 NFKB1 ICAM1
IL23R IL23R IL23R
APOBR APOBR APOBR
GPR35 GPR35 GPR35
ITGB3 FERMT3 EFEMP2
ACAD10 ICOSLG ACAD10
ACAD10 SULT1A2 ACAD10
GPR35 SMAD3 SMAD3
ICAM3 FERMT3 ICAM3
GPR65 CCR2 GPR65
ACAD10 IRF5 FERMT3
REL IFIH1 TNFSF18
IFIH1 IRGM SP110
ERAP1 IRGM SP110
ERAP1 IRGM IRGM
APOBR APOBR APOBR
TNFAIP3 NFKB1 CD40
TAGAP FERMT3 FOS
IL12B IL12B IL12B
IL12B IL12B IL12B
IL2 IL2 IL2
IL2 IL3 IL3
BACH2 SOCS1 BACH2
BACH2 FERMT3 FERMT3
IL21 IL3 IL3
IL21 IL21 IL21
SH2B3 C5orf62 SPRED2
IL21 IL21 IL21
BACH2 IKZF1 IKZF1
CD28 CD28 BACH2
Figure 3.27.: Enriched genesets for every disease that are specific for exactly 3 diseases
(according to DEPICT). The colors correspond to the legend in figure 3.24. The
heatmap cells are annotated with the gene that contributes the most to the
enrichment of the term in a disease.
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PIAS3 PPI subnetwork
REACTOME_IRAK2_MEDIATED_ACTIVATION_OF_TAK1_COMPLEX_UPON_TLR78_OR_9_STIMULA
increased susceptibility to viral infection induced morbidity/mortality
positive regulation of NF−kappaB transcription factor activity
toll−like receptor 3 signaling pathway
toll−like receptor 1 signaling pathway
toll−like receptor 2 signaling pathway
abnormal circulating chemokine level
regulation of transcription factor import into nucleus
transcription factor import into nucleus
tumor necrosis factor production
regulation of tumor necrosis factor production
ITGAL PPI subnetwork
tumor necrosis factor superfamily cytokine production
abnormal myelopoiesis
increased eosinophil cell number
immunoglobulin mediated immune response
B cell mediated immunity
decreased CD4−positive T cell number
B cell activation involved in immune response
regulation of myeloid leukocyte differentiation
regulation of myeloid cell differentiation
immunoglobulin production
positive regulation of osteoclast differentiation
positive regulation of myeloid leukocyte differentiation
CSF1 PPI subnetwork
negative regulation of T cell activation
decreased NK cell number
decreased memory T cell number
abnormal microglial cell morphology
REACTOME_INTERFERON_GAMMA_SIGNALING
activation of innate immune response
decreased circulating interleukin−6 level
REACTOME_INTERLEUKIN:1_SIGNALING
I−kappaB kinase/NF−kappaB cascade
REACTOME_NOD12_SIGNALING_PATHWAY
JAK−STAT cascade
response to molecule of bacterial origin
response to lipopolysaccharide
decreased susceptibility to induced arthritis
abnormal spleen red pulp morphology
decreased interleukin−1 beta secretion
abnormal Langerhans cell physiology
IL6ST PPI subnetwork
impaired macrophage chemotaxis
REACTOME_INNATE_IMMUNE_SYSTEM
PLAGL2 REL STAT5B STAT5B
TYK2 TYK2 ZFP91 ZFP91
TRAFD1 IFIH1 IFIH1 TRAFD1
TYK2 TYK2 ICOSLG ICOSLG
TYK2 TYK2 CCNY ZNF513
NICN1 TYK2 CCNY CCNY
NICN1 TYK2 CCNY CCNY
NOS2 NFKBIA CCL20 CCL20
BSN−AS2 IFIH1 IL19 UBAC2
NOS2 IFIH1 IL19 IL19
AZI2 GCA FCGR2B NOD2
AZI2 GCA FCGR2B NOD2
ICAM4 ICAM4 FERMT3 FERMT3
AZI2 TAGAP FCGR2B NOD2
CXCR1 CARD9 FERMT3 FERMT3
IL2RA GPR65 CSF2 CSF2
IL21 ENSG00000258867 IL21 IL21
IL21 ENSG00000258867 FCGR2B FCGR2B
UBASH3A TNFSF8 CD6 CD6
IL21 FAM205A IL21 IL21
CD226 B3GNT2 FAM132A FAM132A
ENSG00000238164 ICAM4 FAM132A FAM132A
IL21 SLC9A8 IL21 IL21
CD226 IL23R IL23R IL23R
CD226 IL23R C5orf62 CD226
ICAM5 ICAM5 USP25 KSR1
ZNF831 TAGAP ENSG00000255479ENSG00000255479
GPBAR1 ERAP1 C5orf56 CTSW
IL2RA IL2RA IL18RAP IL18RAP
IL21 HSD3B7 CSF2 CCL7
TRAFD1 IFIH1 IRF1 IRF1
IL6R TAGAP CCR2 NOD2
ICAM1 ICAM1 CCL20 CCL2
ICAM1 TNFAIP3 CCL20 RIPK2
TYK2 TYK2 C5orf56 IFNGR2
ICAM1 NFKBIA CCL20 CCL20
IL27 NOS2 C5orf56 C5orf56
NOS2 NOS2 DNAJC27−AS1 CXCR1
NOS2 NOS2 DNAJC27−AS1 CXCR1
GPR65 ICAM1 GPR65 GPR65
RUNX3 IL2RA CSF2 IL2RA
ICAM1 ICAM1 CCRL2 CCL7
TNFSF8 IL2RA IL21 IL21
NOS2 IL2RA CSF2 CSF2
ICAM1 ICAM1 TNFSF15 CCL7
NFKB1 IFIH1 IFIH1 SP110
* UPON_TLR79_OR_9_STIMULATION
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Figure 3.28.: Enriched genesets for every disease that are specific for exactly 4 diseases
(according to DEPICT). The colors correspond to the legend in figure 3.24. The
heatmap cells are annotated with the gene that contributes the most to the
enrichment of the term in a disease.
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increased circulating interleukin−1 beta level
negative regulation of defense response
positive regulation of innate immune response
positive regulation of adaptive immune response based on somatic recombination of imm
positive regulation of adaptive immune response
cytokine−mediated signaling pathway
regulation of innate immune response
positive regulation of cytokine biosynthetic process
cellular response to cytokine stimulus
leukocyte activation
positive regulation of immune system process
immune effector process
leukocyte activation involved in immune response
cell activation involved in immune response
regulation of immune response
leukocyte mediated immunity
hemopoiesis
increased leukocyte cell number
lymphocyte activation involved in immune response
T cell activation involved in immune response
response to cytokine stimulus
positive regulation of defense response
enlarged spleen
increased monocyte cell number
IL2 PPI subnetwork
regulation of leukocyte mediated immunity
increased neutrophil cell number
lymphocyte homeostasis
leukocyte homeostasis
cytokine production
regulation of cytokine production
T cell activation
lymphocyte activation
regulation of leukocyte activation
regulation of cell activation
positive regulation of immune effector process
regulation of immune effector process
lymphocyte proliferation
leukocyte proliferation
mononuclear cell proliferation
IL2RA IL2RA GPR65 CCRL2 GPR183
SPATA2 BSN−AS2 BSN−AS2 BSN−AS2 BSN−AS2
ZC3H12C GPBAR1 AZI2 CCR2 NOD2
IL12B ICOSLG ENSG00000255479 ICOSLG ICOSLG
IL12B ICOSLG ENSG00000255479 ICOSLG ICOSLG
IFIH1 TRAFD1 TRAFD1 IFIH1 SP110
RNF114 TRAFD1 ENSG00000255479 USP25 NOD2
TAGAP CXCR1 TAGAP C7orf33 ENSG00000254588
IFIH1 TRAFD1 TRAFD1 IFIH1 SP110
TAGAP UBASH3A CCR6 IKZF3 CCR6
TAGAP ZNF831 CCR6 ZNF831 CCR6
IFIH1 GPBAR1 ENSG00000258867 IRF8 GPBAR1
TAGAP GPBAR1 APOBR CCDC88B GPBAR1
TAGAP GPBAR1 APOBR CCDC88B GPBAR1
ICAM3 ZNF831 GPR65 ZNF831 ZNF831
TAGAP ZNF831 APOBR IKZF3 IKZF3
ICAM4 BACH2 ICAM4 FAM132A FAM132A
TNFAIP3 CCL20 ITGAL CCDC88B CCDC88B
REL IL21 IL27 IL21 IL21
REL PTGER4 IL27 IL27 IZUMO1
IFIH1 TRAFD1 ERAP1 IFIH1 SP110
ZC3H12C GPBAR1 ZC3H12C FCGR2C NOD2
ICAM4 SOCS1 ICAM4 IKZF1 IKZF1
TNFAIP3 NFKB1 NFKB1 FERMT3 FERMT3
SOCS1 SOCS1 IL1R2 TNFRSF9 TNFRSF9
IL23R IL21 IL23R CCDC88B CCDC88B
ICAM1 NFKB1 APOBR FERMT3 FERMT3
ICAM3 ENSG00000228037 ICAM3 ENSG00000228037 IKZF3
ICAM3 ENSG00000228037 ICAM3 ENSG00000228037 IKZF3
TAGAP GPBAR1 TNFSF8 CCDC88B NOD2
TAGAP GPBAR1 TNFSF8 CCDC88B NOD2
RUNX3 UBASH3A CCR6 UBASH3A THEMIS
RUNX3 UBASH3A CCR6 IKZF3 CCR6
IL12B ZNF831 CCR6 TNFRSF18 CCR6
TAGAP ZNF831 CCR6 TNFRSF18 TNFRSF18
IL23R IL21 IL27 CCDC88B CCDC88B
IL12B IL21 IL27 IL27 IL27
IL12B IL21 IL27 IL12B IL12B
IL12B IL21 TNFSF8 IL12B IL12B
IL12B IL21 IL27 IL12B IL12B
* recombination of immune receptors built
from immunoglobolin superfamily domains
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Figure 3.29.: Enriched genesets for every disease that are specific for exactly 5 diseases
(according to DEPICT). The colors correspond to the legend in figure 3.24. The
heatmap cells are annotated with the gene that contributes the most to the
enrichment of the term in a disease.
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Epithelial Cells
Membranes
Nasopharynx
Blood Platelets
Cervix Uteri
RIBC2
NKX2−3
BSN−AS2
CD226
MIR21
Figure 3.31.: Enriched tissues for every disease that are specific for a single disease. No
significant tissues were detected that are exclusively specific for psoriasis or
PSC. The colors correspond to the legend in figure 3.24. The heatmap cells are
annotated with the gene that contributes the strongest signal to the enrichment
of the tissue in a disease.
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Connective Tissue Cells
Mucous Membrane
Intestinal Mucosa
Macrophages  Alveolar
Antibody Producing Cells
B Lymphocytes
Lymphoid Progenitor Cells
Precursor Cells  B Lymphoid
HSD3B7 AZI2
NKX2−3 FAM55A
ITLN1 FAM55A
CCRL2 SH2D4B
ZPBP2 ZPBP2
ZPBP2 ZPBP2
ICOSLG BACH2
ICOSLG BACH2
Figure 3.32.: Enriched tissues for every disease that are specific for a exactly 2 diseases. The
colors correspond to the legend in figure 3.24. The heatmap cells are annotated
with the gene that contributes the strongest signal to the enrichment of the
tissue in a disease.
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Granulocyte Precursor Cells
Myeloid Progenitor Cells
Colon  Sigmoid
Gastrointestinal Tract
Cecum
Colon
Intestine  Large
Intestines
Lower Gastrointestinal Tract
Pharynx
Palatine Tonsil
Oropharynx
Monocyte Macrophage Precursor Cells
Hematopoietic Stem Cells
Connective Tissue
Bone and Bones
Skeleton
Bone Marrow
IL23R IL23R IL23R
ICAM4 ICAM4 PSMG1
GPR35 GPR35 SLC26A3
NKX2−3 NKX2−3 SLC26A3
ITLN1 ITLN1 RNF186
CCL11 ITLN1 SLC26A3
CCL11 ITLN1 SLC26A3
ITLN1 ITLN1 SLC26A3
CCL11 ITLN1 SLC26A3
ENSG00000254275 ADAD1 HORMAD2
CCR6 BACH2 ZPBP2
CCR6 BACH2 ZPBP2
CCL7 POFUT1 IRGM
ICAM4 ICAM4 HHEX
IRGM ICAM3 IRGM
IRGM ICAM3 IRGM
IRGM ICAM3 IRGM
SH2D4B ICAM3 IRGM
Figure 3.33.: Enriched tissues for every disease that are specific for a exactly 3 diseases. The
colors correspond to the legend in figure 3.24. The heatmap cells are annotated
with the gene that contributes the strongest signal to the enrichment of the
tissue in a disease.
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T Lymphocytes  Regulatory
CD4 Positive T Lymphocytes
Rectum
Intestine  Small
Lymph Nodes
Lymphocytes
Granulocyte Macrophage Progenitor Cells
Neutrophils
Granulocytes
ZNF831 ZNF831 ZNF831 IL2RA
ZNF831 ZNF831 ZNF831 IL2RA
CCL11 ITLN1 SLC26A3 GPR35
NKX2−3 NKX2−3 NKX2−3 NKX2−3
CCL21 IL21 IL21 REL
IL2 CD28 CD28 RUNX3
CCL7 POFUT1 IRGM ICAM4
CXCR1 ERN1 MTMR3 TAGAP
CXCR1 ERN1 MTMR3 TAGAP
Figure 3.34.: Enriched tissues for every disease that are specific for a exactly 4 diseases. The
colors correspond to the legend in figure 3.24. The heatmap cells are annotated
with the gene that contributes the strongest signal to the enrichment of the
tissue in a disease.
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S PS
Lymphoid Tissue
T Lymphocytes
Killer Cells  Natural
Macrophages
Antigen Presenting Cells
Dendritic Cells
Fetal Blood
Immune System
Blood
Leukocytes  Mononuclear
Leukocytes
Blood Cells
Synovial Fluid
Mononuclear Phagocyte System
Monocytes
Phagocytes
Myeloid Cells
Bone Marrow Cells
Hematopoietic System
CCL21 IL21 IL21 CCL21 IL2RA
IL2 IL2 IL2 TNFSF8 IL2RA
CTSW IL2RA IFNG CMC1 IL2RA
CCL7 SH2B3 CCRL2 CARD9 STX4
IL12B GPR35 IL12B CARD9 IL12B
IL12B GPR35 IL12B CARD9 IL12B
RNF123 RNF123 RNF123 RNF123 ICAM4
CTSW TNFRSF14 CCR2 TAGAP TAGAP
IRGM GPBAR1 IRGM TAGAP TAGAP
TNFSF8 ENSG00000228037 CCR2 TNFSF8 RUNX3
TNFSF8 ENSG00000228037ENSG00000228037 TNFSF8 TAGAP
TNFSF8 CD28 CCR2 TNFSF8 TAGAP
IFNG CD28 CD28 TNFSF8 IL12B
IL10 GPR35 CCRL2 CARD9 IL12B
IL10 GPR35 IL10 GPR35 IL12B
APOBR GPR35 CCRL2 APOBR STX4
APOBR GPR35 CCRL2 APOBR STX4
APOBR CXCR1 FCGR2C APOBR ICAM1
APOBR CXCR1 FCGR2C APOBR ICAM1
Figure 3.35.: Enriched tissues for every disease that are specific for a exactly 5 diseases. The
colors correspond to the legend in figure 3.24. The heatmap cells are annotated
with the gene that contributes the strongest signal to the enrichment of the
tissue in a disease.
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3.2.4. Enrichment Analyses
To better understand the networks on a biological level, the functional description of
every protein in ﬁgure 3.37 was looked up on UniProt. It was observed that almost all of
the proteins had something to do with regulation or signaling. Table 3.10 lists details
about the proteins. A systematic analysis of all proteins in the network using DAVID
also resulted in many enriched genesets that have something to do with regulation or
signaling (details not shown).
Table 3.10.: Descriptions of proteins in the largest connected component in the DEPICT-based
network (Figure 3.37). The functional descriptions were taken from uniprot.org
Protein functional category
TYK2_HUMAN Probably involved in intracellular sig-
nal transduction by being involved in
the initiation of type I IFN signaling
ITAL_HUMAN [...] receptor [...] It is involved in a
variety of immune phenomena includ-
ing leukocyte-endothelial cell interac-
tion, cytotoxic T-cell mediated killing,
and antibody dependent killing by gran-
ulocytes and monocytes.
NOTC1_HUMAN regulate[s] cell-fate determination
IRF1_HUMAN Transcriptional regulator which dis-
plays a remarkable functional diversity
in the regulation of cellular responses.
OSMR_HUMAN Capable of transducing OSM-speciﬁc
signaling events.
IKBA_HUMAN Inhibits the activity of dimeric
NFκB/REL complexes by trapping
REL dimers
(continued on next page)
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FOXO1_HUMAN Transcription factor that is the main
target of insulin signaling and regu-
lates metabolic homeostasis in response
to oxidative stress.
IFIH1_HUMAN Innate immune receptor [...] plays a ma-
jor role in sensing viral infection and
in the activation of a cascade of antivi-
ral responses including the induction of
type I interferons and proinflamma-
tory cytokines.
CCR5_HUMAN Receptor for a number of inﬂammatory
CC-chemokines
NFAC1_HUMAN Plays a role in the inducible expression
of cytokine genes in T-cells
TNR6_HUMAN Receptor for TNFSF6/FASLG. [...] The
resulting death- inducing signaling
complex (DISC)
CCR2_HUMAN Receptor for the CCL2, CCL7 and
CCL13 chemokines.
STAT3_HUMAN Signal transducer and transcription
activator
CREM_HUMAN Transcriptional regulator that
binds the cAMP response element
(CRE), a sequence present in many
viral and cellular promoters. Isoforms
are either transcriptional activators or
repressors.
PTN11_HUMAN Acts downstream [...] to participate in
the signal transduction
(continued on next page)
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M3K8_HUMAN [...] activation of the MAPK/ERK path-
way in macrophages, thus being criti-
cal for production of the proinflam-
matory cytokine TNF-alpha (TNF)
during immune responses.
ETS1_HUMAN Directly controls the expression of cy-
tokine and chemokine genes in a
wide variety of diﬀerent cellular con-
texts
IRF8_HUMAN Plays a negative regulatory role in
cells of the immune system
KPCB_HUMAN involved in various cellular processes
such as regulation of the B-cell recep-
tor (BCR) signalosome
JAK2_HUMAN Mediates essential signaling
events in both innate and adaptive
immunity
TLR4_HUMAN Cooperates with LY96 and CD14 to
mediate the innate immune response
[...] Acts via MYD88 [...], leading to
NFκB activation, cytokine secretion
and the inﬂammatory response
STA5B_HUMAN Carries out a dual function: signal
transduction and activation of tran-
scription
FOSL2_HUMAN Controls osteoclast survival and size.
As a dimer with JUN, activates LIF
transcription
(continued on next page)
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ICAM1_HUMAN ICAM1 engagement promotes the
assembly of endothelial apical cups
through ARHGEF26/SGEF and
RHOG activation
ASXL1_HUMAN involved in transcriptional regulation
mediated by ligand -bound nuclear hor-
mone receptors
STA5A_HUMAN Carries out a dual function: signal
transduction and activation of tran-
scription
SOCS1_HUMAN SOCS family proteins form part of
a classical negative feedback sys-
tem that regulates cytokine signal
transduction
IRF5_HUMAN involved in the induction of interfer-
ons IFNA and INFB and inﬂammatory
cytokines upon virus infection
PTN2_HUMAN Negatively regulates numerous
signaling pathways and biological
processes like hematopoiesis, inﬂam-
matory response, cell proliferation and
diﬀerentiation, and glucose homeosta-
sis.
SMAD3_HUMAN Receptor-regulated SMAD (R-SMAD)
that is an intracellular signal trans-
ducer and transcriptional modulator
activated by TGF-beta (transforming
growth factor) and activin type 1 recep-
tor kinases.
(continued on next page)
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IL23R_HUMAN Binds IL23 and mediates T-cells,
NK cells and possibly certain
macrophage/myeloid cells stimula-
tion probably through activation of the
Jak-Stat signaling cascade.
ICAM3_HUMAN ICAM proteins are ligands for the leuko-
cyte adhesion protein LFA-1 (integrin
α-L/β-2). ICAM3 is also a ligand for
integrin αD/β2.
FOS_HUMAN On TGF-beta activation, [...] to regu-
late TGF-beta- mediated signaling. [...]
It is thought to have an important role
in signal transduction.
RUNX3_HUMAN binds to the core site [...] of a number
of enhancers and promoters, including
T-cell receptor enhancers
IL2RA_HUMAN Receptor for interleukin-2. → IL2: this
protein is required for T-cell prolifer-
ation and other activities crucial to
regulation of the immune response
NFKB1_HUMAN is the endpoint of a series of signal
transduction events that are initi-
ated by a vast array of stimuli related
to many biological processes such as in-
ﬂammation
3.2.5. Disease-specific subnetworks
To get a clearer picture of the parts of the network that are speciﬁc to a disease, the
largest connected component was ﬁltered down for every disease to only contain nodes
that are associated with the disease in question and neighboring nodes that are directly
linked to such disease-nodes. In the case of Crohn’s disease and Ulcerative colitis no
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Disease Disease nodes Neighbours Total network size
ankylosing spondylitis 29 382 411
Crohn’s disease 88 825 913
psoriasis 16 186 202
primary sclerosing cholangitis 15 209 224
ulcerative colitis 56 625 681
Table 3.11.: Number of disease-associated nodes and non-disease linker nodes for every disease
(according to DEPICT). A non-disease linker node is a neighbour node of a
disease node and may be associated with another disease.
neighbors were included because of the already great number of directly associated genes.
The subnetworks can be seen in ﬁgures 3.39 to 3.43.
3.2.6. Linker nodes
In order to discover new potential disease genes, all nodes associated with a speciﬁc
disease (according to DEPICT) were taken and the direct neighbours in the global
protein interaction network (CPDB version 30) were taken as linker nodes to create new
subnetworks. There are a great number of linker genes for every disease subnetwork. The
sizes of these networks are listed in table 3.11.
In order to prioritise potential new disease genes, each of the linker node was given a
score that is deﬁned as the number of neighbours that are already associated with the
disease in question, divided by the total number of neighbours. The division operation
was performed to account for hub genes which have a great number of interactors and
therefore a single interaction with a disease gene is not notable.
Tables 3.12 to 3.16 show the best-scoring non-disease genes/proteins. Most of the
best-scoring linker genes were not associated with any of the ﬁve diseases which makes
them interesting candidates for further analysis. However, only few of the nodes with a
score of 0.5 or better had more than one disease-associated neighbour. Notable exceptions
are IL23A (Crohn’s disease, ulcerative colitis and psoriasis, with two of three neighbour
genes) and IRF6 (ulcerative colitis, two out of two neighbouring genes).
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Protein disease neighbours/total neighbours (score) Other diseases
IL1RA_HUMAN 1/1
ERAP2_HUMAN 1/1 CD, UC
LEUK_HUMAN 1/1
AFG32_HUMAN 1/2
ICAM5_HUMAN 1/2
CNTF_HUMAN 1/2
TMM33_HUMAN 1/2
ITAD_HUMAN 1/2
RPIA_HUMAN 1/2
DERL3_HUMAN 1/2
AL1A1_HUMAN 1/2
ARHGA_HUMAN 1/2
IL23A_HUMAN 1/3
IL6_HUMAN 1/3
CXL13_HUMAN 1/3
RHBT2_HUMAN 1/3
UBA7_HUMAN 1/3
THY1_HUMAN 1/3
...
Table 3.12.: Nodes linked to AS-associated genes. Each node has a score that describes the
ratio of neighbours that are associated with AS to the total number of neighbours.
Only the nodes with the best scores are shown.
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Protein disease neighbours/total neighbours (score) Other diseases
IL1RA_HUMAN 1/1
PAI2_HUMAN 1/1
TNFL4_HUMAN 1/1
SIA7B_HUMAN 1/1
LIMK2_HUMAN 1/1
STAC_HUMAN 1/1
NDUF7_HUMAN 1/1
TPC10_HUMAN 1/1
KCNC4_HUMAN 1/1
GALT4_HUMAN 1/1
TAOK3_HUMAN 1/1
MPC2_HUMAN 1/1
ERAP1_HUMAN 1/1 AS, PS
DLL3_HUMAN 1/1
AGAP2_HUMAN 1/1
GLT15_HUMAN 1/1
LEUK_HUMAN 1/1
NOX4_HUMAN 1/1
IL23A_HUMAN 2/3
...
Table 3.13.: Nodes linked to CD-associated genes. Each node has a score that describes the
ratio of neighbours that are associated with CD to the total number of neighbours.
Only the nodes with the best scores are shown.
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Protein disease neighbours/total neighbours (score) Other diseases
ERAP2_HUMAN 1/1 CD, UC
LEUK_HUMAN 1/1
IL23A_HUMAN 2/3
ITAD_HUMAN 1/2
AL1A1_HUMAN 1/2
I12R1_HUMAN 2/5
ITAL_HUMAN 2/6 AS, UC
IL12A_HUMAN 1/3
RHBT2_HUMAN 1/3
NLRC5_HUMAN 1/3
C1GLC_HUMAN 1/4
MATK_HUMAN 1/4
ITPK1_HUMAN 1/4
ITB2_HUMAN 3/18
ITAM_HUMAN 2/12
...
Table 3.14.: Nodes linked to PS-associated genes. Each node has a score that describes the
ratio of neighbours that are associated with PS to the total number of neighbours.
Only the nodes with the best scores are shown.
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Protein disease neighbours/total neighbours (score) Other diseases
IFNA1_HUMAN 1/2
RPIA_HUMAN 1/2
CD80_HUMAN 1/3
CD86_HUMAN 1/3
GNA14_HUMAN 2/8
ADA1A_HUMAN 2/8
PVRL2_HUMAN 1/5
CBS_HUMAN 1/6
PVR_HUMAN 1/6
ATP5J_HUMAN 1/6
NSF_HUMAN 1/6
SOCS2_HUMAN 1/7
TGFB3_HUMAN 1/7
GNA15_HUMAN 2/15
...
Table 3.15.: Nodes linked to PSC-associated genes. Each node has a score that describes
the ratio of neighbours that are associated with PSC to the total number of
neighbours. Only the nodes with the best scores are shown.
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3.3. Effect directions of Single Nucleotide
Polymorphisms
Disease-associated SNPs can increase or decrease the risk of developing the disease. The
risk itself is only a probability and there are cases of healthy individuals with high genetic
risk scores and also cases of aﬀected individuals with low genetic risk scores (Figure
1.2). The risk scores are based on the frequencies of the alleles in the study populations
in healthy versus disease-aﬀected individuals. The odds ratios obtained from these
frequencies only provide an estimate on the eﬀect size of a SNP. The underlying biological
mechanisms are still unclear. But given that proteins interact with each other to perform
their functions, there might be general principles that increase or decrease the quality of
these interactions and these general principles might be observable on the network level.
A special focus is given on protective variants because it is hypothesized that protective
variants might induce buﬀering in the network against problematic signals.
As described in previous chapters, genetic variants have to be linked to genes to
analyze them on the network level. For this part the linking was done on the basis of
ENCODE transcription factor binding sites (TFBS) annotations. At this point it should
be explained that every ENCODE TFBS is annotated with genes. It was originally
assumed that these genes would be the transcriptional targets of the TFBS but while
writing this thesis it was realised that these genes are the transcription factors or other
proteins that bind to DNA at that speciﬁc location. Unfortunately these annotations do
not contain information about which genes are controlled by the TFBS but they allow
us to link SNPs to transcription factors and other DNA-binding proteins. And these
proteins in turn might lead to enriched pathways. Because of the initial misunderstanding
with the ENCODE annotation ﬁles, some of the results presented here might seem out of
context. However, every transcription factor is still the product of a gene and therefore
the principle of linking SNPs to genes still holds. All results have been corrected to
reﬂect the fact that the ENCODE annotations contain transcription factors but not their
target proteins. Even with this change of perspective, there are some interesting results.
The major advantage of these ENCODE TFBS annotations is that they are manually
curated and that for every binding site it is always known which proteins bind to it.
With the help of the program GoShifter all lead SNPs were mapped to LD SNPs and
then the positional overlap of these LD SNPs with transcription factor binding sites was
determined.
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Protein disease neighbours/total neigbours (score) Other diseases
IL1RA_HUMAN 1/1
RASA2_HUMAN 1/1
TNFL4_HUMAN 1/1
SIA7B_HUMAN 1/1
GTPB1_HUMAN 1/1
IRF6_HUMAN 2/2
KCNC4_HUMAN 1/1
GALT4_HUMAN 1/1
ERAP1_HUMAN 1/1 AS, PS
AGAP2_HUMAN 1/1
PCDA4_HUMAN 1/1
GLT15_HUMAN 1/1
IL23A_HUMAN 2/3
AFG32_HUMAN 1/2
ICAM5_HUMAN 1/2
TMM33_HUMAN 1/2
ST2A1_HUMAN 1/2
TGIF2_HUMAN 1/2
IFNA1_HUMAN 1/2
GSC_HUMAN 1/2
ISG20_HUMAN 1/2
CC90B_HUMAN 1/2
GALT1_HUMAN 1/2
GLT10_HUMAN 1/2
1A03_HUMAN 1/2
I12R2_HUMAN 1/2
INGR2_HUMAN 1/2
I12R1_HUMAN 2/5
FGFR3_HUMAN 2/5
PRDC1_HUMAN 2/5
...
Table 3.16.: Nodes linked to UC-associated genes. Each node has a score that describes the
ratio of neighbours that are associated with UC to the total number of neighbours.
Only the nodes with the best scores are shown.
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ENCODE annotation GoShifter global p-value
Distal H3K4me1 annotations (cell type speciﬁc) 0.0033
Distal H3K27ac annotations (cell type speciﬁc) 0.0053
Distal H3K4me3 annotations (cell type speciﬁc) 0.0143
Distal TF binding sites 0.0145
Proximal TF binding sites 0.0179
Proximal H3K27ac annotations (cell type speciﬁc) 0.0465
Proximal H3K4me1 annotations (cell type speciﬁc) 0.0499
Proximal H3K4me3 annotations (cell type speciﬁc) 0.0634
Distal DNase peaks 0.1025
Proximal DNase peaks 0.1973
Proximal H3K9ac annotations (cell type speciﬁc) 0.2102
Distal H3K9 annotations (cell type speciﬁc) 0.3174
Table 3.17.: ENCODE annotations and the global enrichment p-values of using GoShifter
with these annotations and the 244 cross-disease SNPs
The ENCODE project provides various annotations for genomic regions. Table 3.17
lists all annotations that have been downloaded and tested with GoShifter in combination
with the 244 cross-disease SNPs. It could be observed that some histone markers
(H3K4me1, H3K27ac, H3K4me3, H3K27ac, H3K4me1) and the proximal and distal
transcription factor binding sites have signiﬁcant enrichments given the 244 cross-disease
SNPs. However, the histone marker annotations do not provide information which genes
are regulated by the modiﬁcations. Therefore the histone markers have not been used
for the mapping of SNPs to genes.
Some annotations may be the result of other annotations72. For example, DNase-I
hypersensitive sites tend to be at the same positions as regulatory regions and exonic
sites88. In order to account for such colocating annotations, GoShifter also provides a
stratiﬁed approach, to test annotations for dependence of one another. Figure 3.44 shows
that all but one of the signiﬁcant ENCODE annotations are independent of each other
and can be regarded as primary signals for further analysis.
The classiﬁcation of SNPs into protective and risk variants for every individual disease
was taken from the cross-disease project2. It should be noted that SNPs can be protective
for one disease while at the same time they can be risk-inducing for another.
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Proximal H3K27ac annotations 
(cell type specific) 
Distal H3K4me3 annotations 
(cell type specific) 
Proximal TF binding sites
Proximal H3K4me1 annotations 
(cell type specific) 
Distal H3K27ac annotations (cell 
type specific) 
Distal TF binding sites
Distal H3K4me1 annotations 
(cell type specific) 
Figure 3.44.: Stratification tests of different annotations with GoShifter. Every annotation
that was significant in the normal GoShifter run was tested with all other
significant annotations to determine if one type of annotation is dependent on
another. This was done for every pair of annotations in both directions. For most
pairs of annotations no direction was superior to the other. But for the proximal
H3K4me1 annotations there appears to be a dependence on distal transcription
factor binding sites and also a dependence on distal H3K27ac modifications. Red
arrows indicate dependence and green arrows indicate independence. Arrowheads
indicate the primary annotation that was tested for independence.
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annotation and risk class AS CD PS PSC UC
Proximal TFBS, risk 84 105 58 18 94
Distal TFBS, risk 153 250 92 71 208
Proximal TFBS, protection 60 86 22 33 90
Distal TFBS, protection 100 214 41 63 138
Proximal TFBS, neutral 125 78 189 218 85
Distal TFBS, neutral 293 82 413 412 200
Table 3.18.: Counts of risk classes of LD SNPs overlapping annotations. Neutral LD SNPs
are listed for completeness. They were not used in the following steps.
DNA-binding protein risk class AS CD PS PSC UC
Bindings to only risk variants 19 4 30 24 11
Bindings to only protective variants 3 5 6 5 4
Bindings to both types of variants 121 139 110 106 136
Bindings to sites without eﬀective variants 11 6 8 19 3
Table 3.19.: Risk classifications (based on the minor allele in the study populations from
Ellinghaus et al.2) of DNA-binding proteins for every disease
3.3.1. Mapping of SNPs to genes/DNA binding elements
Because GoShifter does only report which LD SNPs overlap with an annotation but not
the annotation itself, separate scripts have been written to perform the backmapping.
No SNP is located within a distal as well in a proximal TFBS. But according to
the ENCODE annotations a single TFBS of size 150bp can be regulated by several
DNA-binding elements at once. Every LD SNP has only one lead SNP linked to it.
There are 73 shared lead SNPs between distal and proximal transcription factor binding
sites. Based on the LD SNPs there are 149 diﬀerent binding elements linked to proximal
TFBS and 148 diﬀerent binding elements linked to distal TFBS. The intersection of these
aforementioned genes (binding elements) contains 143 genes and the total number of
linked genes is thus 154.
Table 3.18 lists the numbers of SNPs that overlap a TFBS annotation together with
their risk status. In any case the number of SNPs in distal TFBSs is greater than the
number of SNPs in proximal TFBS. With the minor exception of 4 TFBSs, all TFBS
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3.3.3. Purely Protective Binding Factors
Table 3.20.: Best DAVID enrichment results for genes with only protective variants in TFBSs.
Term term category #genes Corrected
p-value
transcription regulation SP_PIR_KEYWORDS 11 7e-08
Transcription SP_PIR_KEYWORDS 11 4.4e-08
transcription regulator activity GOTERM_MF_FAT 11 3.1e-07
regulation of transcription GOTERM_BP_FAT 12 3.8e-06
regulation of transcription, GOTERM_BP_FAT 11 2.1e-06
DNA-dependent
regulation of RNA metabolic process GOTERM_BP_FAT 11 1.7e-06
nucleus SP_PIR_KEYWORDS 12 9.5e-07
transcription GOTERM_BP_FAT 10 0.00015
DNA binding GOTERM_MF_FAT 10 0.00017
sequence-speciﬁc DNA binding GOTERM_MF_FAT 7 0.00013
dna-binding SP_PIR_KEYWORDS 8 0.00016
transcription factor activity GOTERM_MF_FAT 7 0.001
negative regulation of GOTERM_BP_FAT 5 0.0056
transcription, DNA-dependent
negative regulation of RNA GOTERM_BP_FAT 5 0.0052
metabolic process
negative regulation of GOTERM_BP_FAT 5 0.012
transcription
negative regulation of gene GOTERM_BP_FAT 5 0.015
expression
negative regulation of nucleobase, GOTERM_BP_FAT 5 0.014
(continued on next page)
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nucleoside, nucleotide and nucleic
acid metabolic process
negative regulation of nitrogen GOTERM_BP_FAT 5 0.014
compound metabolic process
negative regulation of GOTERM_BP_FAT 5 0.015
macromolecule biosynthetic process
negative regulation of cellular GOTERM_BP_FAT 5 0.016
biosynthetic process
negative regulation of GOTERM_BP_FAT 5 0.016
biosynthetic process
negative regulation of GOTERM_BP_FAT 5 0.033
macromolecule metabolic process
cell fate commitment GOTERM_BP_FAT 3 0.073
negative regulation of GOTERM_BP_FAT 3 0.16
transcription from RNA polymerase
II promoter
positive regulation of gene GOTERM_BP_FAT 7 0.00014
expression
positive regulation of GOTERM_BP_FAT 7 0.0011
macromolecule metabolic process
regulation of transcription from GOTERM_BP_FAT 5 0.034
RNA polymerase II promoter
positive regulation of GOTERM_BP_FAT 3 0.033
gene-speciﬁc transcription
regulation of gene-speciﬁc GOTERM_BP_FAT 3 0.071
transcription
(continued on next page)
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positive regulation of GOTERM_BP_FAT 4 0.075
transcription, DNA-dependent
positive regulation of RNA GOTERM_BP_FAT 4 0.073
metabolic process
transcription factor binding GOTERM_MF_FAT 4 0.068
positive regulation of GOTERM_BP_FAT 4 0.1
transcription
positive regulation of nucleobase, GOTERM_BP_FAT 4 0.13
nucleoside, nucleotide and nucleic
acid metabolic process
positive regulation of nitrogen GOTERM_BP_FAT 4 0.13
compound metabolic process
positive regulation of GOTERM_BP_FAT 4 0.14
macromolecule biosynthetic process
positive regulation of cellular GOTERM_BP_FAT 4 0.15
biosynthetic process
positive regulation of GOTERM_BP_FAT 4 0.15
biosynthetic process
positive regulation of GOTERM_BP_FAT 3 0.26
transcription from RNA polymerase
II promoter
receptor SP_PIR_KEYWORDS 4 0.17
zinc ﬁnger region:NR C4-type UP_SEQ_FEATURE 3 0.024
DNA-binding region:Nuclear receptor UP_SEQ_FEATURE 3 0.024
Zinc ﬁnger, nuclear hormone INTERPRO 3 0.018
receptor-type
(continued on next page)
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Steroid hormone receptor INTERPRO 3 0.0097
Nuclear hormone receptor, INTERPRO 3 0.0067
ligand-binding, core
Nuclear hormone receptor, INTERPRO 3 0.0067
ligand-binding
Zinc ﬁnger, NHR/GATA-type INTERPRO 3 0.0057
steroid hormone receptor activity GOTERM_MF_FAT 3 0.01
ZnF_C4 SMART 3 0.012
HOLI SMART 3 0.0067
promoter binding GOTERM_MF_FAT 3 0.012
ligand-dependent nuclear receptor GOTERM_MF_FAT 3 0.01
activity
zinc ﬁnger SP_PIR_KEYWORDS 3 0.02
zinc SP_PIR_KEYWORDS 6 0.026
zinc-ﬁnger SP_PIR_KEYWORDS 5 0.059
DNA binding SP_PIR_KEYWORDS 3 0.065
metal-binding SP_PIR_KEYWORDS 6 0.068
zinc ion binding GOTERM_MF_FAT 6 0.22
receptor SP_PIR_KEYWORDS 4 0.17
transition metal ion binding GOTERM_MF_FAT 6 0.33
metal ion binding GOTERM_MF_FAT 6 0.79
cation binding GOTERM_MF_FAT 6 0.78
ion binding GOTERM_MF_FAT 6 0.77
The number of transcription factors that only target protective variants is relatively
low (Table 3.19). While keeping this in mind, an enrichment analysis with DAVID
was done (Table 3.20). All twelve ”protective” genes are annotated with ”regulation of
transcription” and with ”nucleus” conﬁrming their roles as regulators which is further
supported by the other annotation terms in the ﬁrst and second cluster which are all
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NDF1_HUMAN
NR4A2_HUMAN
CAND1_HUMAN
SMRC1_HUMAN
CHMP5_HUMAN
NR1H2_HUMAN
MEP50_HUMAN
CHD7_HUMAN
MARK4_HUMAN
DBP_HUMAN
CREB1_HUMAN
KLF1_HUMAN
REQU_HUMAN
STAT2_HUMAN
IF16_HUMAN
SETD7_HUMAN
MAML1_HUMAN
CARM1_HUMAN
BTF3_HUMAN
NONO_HUMAN
PML_HUMAN
STAT3_HUMAN
PCNA_HUMAN
NGN2_HUMAN
SMCA1_HUMAN
ARID2_HUMAN
PB1_HUMAN
BRWD1_HUMAN
PHF10_HUMAN
ARI1A_HUMAN
HIC1_HUMAN
HDAC9_HUMAN
TERT_HUMAN
MYCD_HUMAN
FANCA_HUMAN
FBX6_HUMAN
ZMIZ2_HUMAN
VDR_HUMAN
SMRD2_HUMAN
RFA1_HUMAN
MYOG_HUMAN
RBL2_HUMAN
SMCA4_HUMAN 
H32_HUMAN
CDYL1_HUMAN
NF1_HUMAN
TOPB1_HUMAN
CHD3_HUMAN
HDAC1_HUMAN
SNF5_HUMAN
CHD4_HUMAN
RCOR1_HUMAN
DPF1_HUMAN
BRCA1_HUMAN HDAC2_HUMAN
1433E_HUMAN
BAZ1B_HUMANRPB1_HUMAN
SIN3B_HUMAN
HDAC3_HUMAN
H2AX_HUMAN
CSN5_HUMANSTA5A_HUMAN
XRCC5_HUMAN
HSF1_HUMAN 
RUVB2_HUMAN
RBBP4_HUMAN
KCC2G_HUMAN
NPM_HUMAN
RUVB1_HUMAN
ACTB_HUMAN
ING1_HUMAN
CTNB1_HUMANCUL3_HUMAN
DDX5_HUMAN
H33_HUMAN
TOP2A_HUMAN
SMAD3_HUMAN
CDK8_HUMAN
GRB2_HUMANHNRPC_HUMAN TIF1B_HUMAN
HSPB1_HUMAN
SMCE1_HUMAN
BCL3_HUMAN
P53_HUMAN
USF1_HUMAN
MAPK2_HUMAN
ROA1_HUMAN
RL4_HUMAN
ATD3A_HUMAN TSC1_HUMAN
SPTB2_HUMAN
DHX9_HUMAN
SKP1_HUMAN
SMRC2_HUMAN
CDN1A_HUMAN
RL3_HUMAN SIN3A_HUMAN
RS13_HUMANMED10_HUMAN
NSF_HUMAN
ANDR_HUMAN
FLNB_HUMAN
AHR_HUMAN
RL6_HUMAN
SMAD2_HUMAN
CEBPA
SMCA2_HUMAN
MDM2_HUMAN
CHIP_HUMAN
TBL1R_HUMAN
RING2_HUMAN
NCOR2_HUMAN
MYC_HUMAN
PRKDC_HUMAN
SMC1A_HUMAN
COM1_HUMAN
TEAD3_HUMAN
ZN217_HUMAN
TNR6_HUMAN
SOX6_HUMAN
T2AG_HUMAN
KCC2D_HUMAN
PLCB1_HUMAN
MK10_HUMAN
SNAI2_HUMAN
H2A2C_HUMAN
RPN1_HUMAN
RL5_HUMAN
PHB_HUMAN
TAF10_HUMAN
BRD7_HUMAN
PAX6_HUMAN
PBX1_HUMAN
REST_HUMAN
JUNB_HUMAN
HEY2_HUMAN
CREST_HUMAN
SIR7_HUMAN
IKZF1_HUMAN
HSF4_HUMAN
EF1G_HUMAN
TCP4_HUMAN
MK08_HUMANXPC_HUMAN
H31T_HUMAN
KCC2B_HUMAN
TAF9_HUMAN
TAF7_HUMAN
DNJB1_HUMAN
PRDM1_HUMAN 
TLE2_HUMAN
BACH1_HUMAN 
APC5_HUMAN CREM_HUMAN
AES_HUMAN
BATF_HUMAN
RBL1_HUMAN
ACL6A_HUMAN
TFE2_HUMAN
KS6A5_HUMAN
KDM6A_HUMAN
NF2L2_HUMAN
ZEB1_HUMAN
EPAS1_HUMAN
IRF1_HUMAN
PDS5A_HUMAN
SMC2_HUMAN
DPOD3_HUMAN
CDC27_HUMAN
TCPA_HUMAN
RAD21_HUMAN
H2A2B_HUMAN
TCOF_HUMAN
BRE1A_HUMAN
K2C3_HUMAN
LARP7_HUMAN
PSMD2_HUMAN
SMC3_HUMAN
CCAR2_HUMAN
SMC4_HUMAN
UBP7_HUMAN
UB2D1_HUMAN
WAC_HUMAN
APC1_HUMAN
U520_HUMAN
PARP2_HUMAN
LMNA_HUMAN
H2A1_HUMAN
APC7_HUMAN
WAPL_HUMAN
DPOD2_HUMAN
MSH6_HUMAN
HSP72_HUMAN
RAD50_HUMAN
H2AY_HUMAN
PRS10_HUMAN
CND1_HUMAN
PRP8_HUMAN
HNRH1_HUMAN
PCGF2_HUMAN
PLK1_HUMAN
SIR6_HUMAN 
CSK21_HUMAN
UBB_HUMAN
MK09_HUMAN
WDHD1_HUMAN
TAF1_HUMAN
RPR1A_HUMAN
TCPE_HUMAN
SART3_HUMAN
SPT5H_HUMAN
MATR3_HUMAN
MSH2_HUMAN
KIF4A_HUMAN
LMNB1_HUMAN
CBX5_HUMAN
MBD3_HUMAN
CCNE1_HUMAN
IKKE_HUMAN
BRD4_HUMAN
1433Z_HUMAN
C2TA_HUMAN
H31_HUMAN
ETS2_HUMAN ANM5_HUMAN
NFKB2_HUMAN
ARI1B_HUMAN
WWOX_HUMAN
CPSF2_HUMAN
SRF_HUMAN
SMRCD_HUMAN
BCL6_HUMAN
STAT1_HUMAN
RELB_HUMAN
PRI1_HUMAN SSXT_HUMAN
RUNX1_HUMAN
ATF3_HUMAN
RAP1A_HUMAN
IMA1_HUMAN
TBX5_HUMAN
SUH_HUMAN
PMS2_HUMAN
BMI1_HUMAN
ADDA_HUMAN
GATA1_HUMAN
STK11_HUMAN
DPF3_HUMAN
GEMI_HUMAN
CHFR_HUMAN
EED_HUMAN
NOTC1_HUMAN
NSD3_HUMAN
ACTC_HUMAN
PABP2_HUMAN
MPH6_HUMAN
PKCB1_HUMAN
H2B2E_HUMAN
CDX2_HUMAN
KLF4_HUMAN
RFC1_HUMAN
GA45G_HUMAN
SRBP1_HUMAN
TBA1A_HUMAN
STRN_HUMAN
RS20_HUMAN
NR2C1_HUMAN
RT29_HUMAN
SRRM1_HUMAN
GNAI3_HUMAN
RL10A_HUMAN
ANM2_HUMAN
HS90A_HUMAN
IF4A1_HUMANGRIP1_HUMANNR2C2_HUMAN
CENPR_HUMAN
ATPB_HUMAN
CPSF5_HUMAN
RS14_HUMAN
CUL4B_HUMAN
HDAC4_HUMAN
NCOR1_HUMAN
MK01_HUMAN
SMRD1_HUMAN
TOP2B_HUMAN
RL21_HUMAN
RL29_HUMAN
PAK1_HUMAN
FOXM1_HUMAN
NDRG2_HUMAN
RARA_HUMAN
ADT2_HUMAN
CLH1_HUMAN
MED6_HUMAN
RL8_HUMAN
NU153_HUMAN
PP1G_HUMANGBLP_HUMANCALM_HUMAN
TERA_HUMAN
MED21_HUMAN
AAPK2_HUMAN
SFPQ_HUMAN
AAPK1_HUMAN
ERR3_HUMAN
NUCL_HUMAN
SRSF4_HUMAN
KPCE_HUMANNANOG_HUMAN 
NRF1_HUMAN
RORG_HUMAN
NR5A2_HUMANPPARD_HUMAN
MED12_HUMAN PPARA_HUMAN
HCFC1_HUMAN
MED20_HUMAN
MBB1A_HUMAN
USF2_HUMAN
RNF34_HUMAN
STF1_HUMAN
TWST1_HUMAN
MYEF2_HUMAN
NR1I2_HUMAN
NR1I3_HUMAN
RNF4_HUMAN
ERBB2_HUMAN
RS24_HUMAN
RS23_HUMAN
MEN1_HUMAN
SAFB1_HUMAN
ASH2L_HUMAN
RPN2_HUMANEZH2_HUMAN
NFKB1_HUMAN
PIAS1_HU ANMK14_HUMAN
ATX1_HUMAN
EXOS6_HUMAN
DUT_HUMAN
Z658B_HUMAN
NXF1_HUMAN
ZN606_HUMAN
EP300_HUMAN
THA_HUMAN
PRGC1_HUMAN 
NRIP1_HUMAN
CCNH_HUMAN
KAT2A_HUMAN
CLH2_HUMAN
GNAI2_HUMAN
SF01_HUMAN
MED1_HUMAN
NR1H4_HUMAN
NR2F6_HUMAN
MED14_HUMAN
HNF4A_HUMAN
SYK_HUMAN
MED16_HUMAN
NCOA6_HUMAN
NCOA3_HUMAN
NR0B1_HUMAN
ESR2_HUMAN
ZHANG_HUMAN
FBXW7_HUMAN
LPPRC_HUMAN
SALL4_HUMAN
CAPZB_HUMAN
RS3A_HUMAN
SKI_HUMAN
TBB5_HUMAN
SC61B_HUMAN
CAPR1_HUMAN
MED13_HUMAN
RBX1_HUMAN
MED23_HUMAN
FOXO3_HUMAN
LYRIC_HUMANROA0_ U AN
ZBT17_HUMAN
SEPT2_HUMAN
MYH14_HUMAN
CACL1_HUMAN
RL24_HUMAN
CAV1_HUMAN
RL37A_HUMAN
PLAK_HUMAN
GA45A_HUMAN
ROA3_HUMANLMO4_HUMAN
RS15A_HUMAN
K1C19_HUMAN
GDIR1_HUMAN
HS90B_HUMAN
TRXR1_HUMAN
SPOP_HUMAN
PTMA_HUMAN
RL7_HUMAN
U2AF2_HUMAN
WDR5_HUMAN
2AAA_HUMAN
PELP1_HUMAN
TBA1C_HUMAN
P85A_HUMAN
RL27A_HUMAN
RS18_HUMAN
RS12_HUMAN
MYLK2_HUMAN
1433T_HUMAN
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Figure 3.46.: Protein-Protein interactions between ”protective genes” and their direct inter-
action partners. The protective genes/proteins are shown in green and the
interaction partners are shown in blue. ESR1 is directly connected to ERR1,
PRGC1 and SMCA4. ERR1 is furthermore connected to PRGC1 and HSF1 is
connected to SMCA4.
related to DNA binding and transcription. Cluster 3 contains many terms that are related
to negative regulation. The last two terms in cluster 3 are above the benjamini-hochberg
signiﬁcance threshold. Cluster 4 is somewhat the counterpart of Cluster 3 because it
contains many terms for positive regulation. But most terms are above the signiﬁcance
threshold. Finally there is cluster 5 which consists of terms that are related to zinc-ﬁnger
transcription factors and steroid hormone receptors.
In the following text the term ”protective gene” will refer to transcription factors
whose TFBSs contain protective but no risk variants for speciﬁc diseases. Conversely,
”risk genes” will refer to transcription factors whose TFBSs contain risk variants but no
protective variants. The term ”mixed gene” refers to transcription factors with both, risk
and protection variants within their TFBSs for a speciﬁc disease.
Eleven of the twelve protective genes/proteins have high-conﬁdence interactions in the
CPDB. They interact with 681 other proteins. Of these 681 proteins 138 interact directly
with more than one of the protective genes. One of these protective genes is the estrogen
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Figure 3.47.: Protective genes (green) and genes that are enriched for the vitamin D receptor
(blue). The benjamini-hochberg-corrected DAVID enrichment p-value is 3−9.
receptor (ESR1) and it should be noted that the estrogen receptor is a hub protein with
445 interaction partners. Figure 3.46 depicts the interactions of these protective genes.
The non-protective interactors in turn have been tested for enrichment with DAVID.
Notable terms include: (regulation of) transcription, nuclear lumen, positive/negative
regulation of gene expression, transcription factor binding, chromatin regulator, Vitamin
D receptor.
The vitamin D receptor is interesting, because Vitamin D deﬁciency has been linked
to inﬂammatory bowel disease89 90 91. Figure 3.47 shows the twelve linker genes that
enrich for the vitamin D receptor. It is known that dendritic cells respond to vitamin D
stimuli and can induce pro- or anti-inﬂammatory responses23.
3.3.4. Protective genes in detail
In the following section the twelve genes/proteins, for which only protective variants
were detected, will be presented in detail.
BACH1
BACH1 is a protective gene for primary sclerosing cholangitis and a risk gene for psoriasis.
In the other three diseases it is a mixed gene.
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BACH1 serves as a transcriptional regulator. It can activate and repress transcrip-
tion92.
BACH1 is similar to BACH2 which is already known to be related to IBD in the
context of oxidative stress23. BACH2 is also present in the heatmaps in the ﬁgures 3.31,
3.33 and 3.35.
COUP transcription factor 2 (COT2_HUMAN)
COT2 is a protective gene in psoriasis and a risk gene in PSC. In other diseases it is a
mixed gene. The full name is COUP transcription factor 2.
CTBP2
CTBP2 is a protective gene in PSC. In all other diseases there are risk but also protective
variants in the TFBSs. According to UniProt it is a ”Corepressor targeting diverse
transcription regulators”. It is involved in the following human KEGG pathways:
• Wnt signaling pathway (hsa04310)
• Notch signaling pathway (hsa04330)
• Pathways in cancer (hsa05200)
• Chronic myeloid leukemia (hsa05220)
CTCFL
This gene is protective in ankylosing spondylitis and ulcerative colitis. For psoriasis only
risk variants are known and primary sclerosing cholangitis is a mixed case. It has no
high-conﬁdence interactions in the ConsensusPathDB. It is responsible for epigenetic
reprogramming93.
ESRRA (ERR1_HUMAN)
Protective in Crohn’s disease and psoriasis. The full name is Steroid hormone receptor
ERR1.
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ESR1
ESR1 is protective in psoriasis while all other diseases have mixed types of risk factors.
ESR1 is the estrogen receptor and is involved in the following KEGG pathways:
• Estrogen signaling pathway (hsa04915)
• Prolactin signaling pathway (hsa04917)
• Thyroid hormone signaling pathway (hsa04919)
• Endocrine and other factor-regulated calcium reabsorption (hsa04961)
• Proteoglycans in cancer (hsa05205)
HSF1
HSF1 is protective in the four diseases AS, PS, PSC and CD. It is mixed for ulcerative
colitis. It is a transcriptional activator94.
NANOG
NANOG is protective in ulcerative colitis. According to UniProt it is a ”Transcription
regulator involved in inner cell mass and embryonic stem (ES) cells proliferation and
self-renewal. ”
PRDM1
PRDM1 is protective in UC, PSC, CD and PS. According to UniProt it is a ”Tran-
scriptional repressor that binds speciﬁcally to the PRDI element in the promoter of the
beta-interferon gene95. [It] Drives the maturation of B-lymphocytes into Ig secreting
cells96.”
PPARGC1A (PRGC1_HUMAN)
PPARGC1A is protective in Crohn’s disease. On UniProt.org it has the following
description:
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Transcriptional coactivator for steroid receptors and nuclear receptors. [...]
Plays an essential role in metabolic reprogramming in response to dietary
availability through coordination of the expression of a wide array of genes
involved in glucose and fatty acid metabolism. Induces the expression of
PERM1 in the skeletal muscle in an ESRRA-dependent manner. [...]
There appear to be interesting connections to diet and estrogen-receptor-related issues.
The protein is involved in the following KEGG pathways:
• AMPK signaling pathway (hsa04152)
• Longevity regulating pathway (hsa04211)
• Insulin signaling pathway (hsa04910)
• Adipocytokine signaling pathway (hsa04920)
• Glucagon signaling pathway (hsa04922)
• Insulin resistance (hsa04931)
• Huntington’s disease (hsa05016)
SIRT6 (SIR6_HUMAN)
SIRT6 is protective in Crohn’s disease while it has only known risk variants in AS and
PS. Is involved in the KEGG pathway ”Central carbon metabolism in cancer (hsa05230)”.
SIRT6 is involved in aging processes and NFκB regulation through histone deacetylation97.
SMARCA4 (SMCA4_HUMAN)
SMARCA4 has protective variants in all diseases. In Crohn’s disease there are also risk
variants. The full name is Transcription activator BRG1.
3.3.5. Comparison with geneset-based networks
A comparison with the genes obtained from using DEPICT in section 3.2 and all DNA
binding elements detected in this section (irregardless of risk status) yielded only an
overlap of nine genes: ETS1, FOSL2, FOS, IRF1, NFAC1, NFKB1, RUNX3, STA5A,
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STAT3. For comparison: The largest connected component from the DEPICT-analysis
(Figure 3.37) consists of 37 nodes and nine of these nodes overlap with the DNA binding
elements from this section. There is no overlap with the mostly unconnected nodes
(Figure 3.38) that were detected based on both, disease-speciﬁc p-values (76 mostly
unconnected nodes) and SBM p-values (80 mostly unconnected nodes).
3.3.6. Network analysis
In order to study the importance of the genes with diﬀerent risk status (protective, risk,
mixed, neutral) in the network, the centrality of every node was determined. For this the
whole CPDB network (version 31, interaction conﬁdence ≥ 0.95) was taken and diﬀerent
centrality measures have been applied to it. The same centrality measures have been
taken for the subnetwork of nodes that are associated with at least one of the ﬁve diseases
(called Cross-disease subgraph). All centrality measures have been calculated with the
networkx python package79. The centralities are: Degree centrality, betweeness centrality,
closeness centrality and eigenvector centrality. Figures 3.48 to 3.52 show a selection of
the distribution of the centralities for the ﬁve diseases. The full set of distribution plots
can be found in the supplementary ﬁgures (digital attachment).
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Figure 3.48.: Top: Distribution of node degree centrality in the complete ConsensusPathDB
(minimum edge confidence 95%) for nodes that are associated with at least one
disease and Bottom: Distribution of node degree centrality in the subgraph of
the ConsensusPathDB that consists only of nodes that are associated with at
least one disease.
Both: The colors of the bars indicate the risk status of all minor variants in
the study population2 that a DNA-binding element interacts with.
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Figure 3.49.: Top: Distribution of node betweenness centrality in the complete Consensus-
PathDB (minimum edge confidence 95%) for nodes that are associated with
at least one disease and Bottom: Distribution of node betweenness centrality
in the subgraph of the ConsensusPathDB that consists only of nodes that are
associated with at least one disease.
Both: The colors of the bars indicate the risk status of all minor variants in
the study population2 that a DNA-binding element interacts with.
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Figure 3.50.: Top: Distribution of node closeness centrality in the complete Consensus-
PathDB (minimum edge confidence 95%) for nodes that are associated with
at least one disease and Bottom: Distribution of node closeness centrality in
the subgraph of the ConsensusPathDB that consists only of nodes that are
associated with at least one disease.
Both: The colors of the bars indicate the risk status of all minor variants in
the study population2 that a DNA-binding element interacts with.
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Figure 3.51.: Top: Distribution of node closeness centrality in the complete Consensus-
PathDB (minimum edge confidence 95%) for nodes that are associated with
at least one disease and Bottom: Distribution of node closeness centrality in
the subgraph of the ConsensusPathDB that consists only of nodes that are
associated with at least one disease.
Both: The colors of the bars indicate the risk status of all minor variants in
the study population2 that a DNA-binding element interacts with.
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Figure 3.52.: Top: Distribution of node eigenvector centrality in the complete Consensus-
PathDB (minimum edge confidence 95%) for nodes that are associated with
at least one disease and Bottom: Distribution of node eigenvector centrality
in the subgraph of the ConsensusPathDB that consists only of nodes that are
associated with at least one disease.
Both: The colors of the bars indicate the risk status of all minor variants in
the study population2 that a DNA-binding element interacts with.
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AS CD PS PSC UC
CTCFL_HUMAN protective mixed risk neutral protective
SIX5_HUMAN mixed mixed risk mixed mixed
SP2_HUMAN risk mixed risk risk mixed
SP4_HUMAN risk mixed risk risk mixed
Table 3.21.: Risk status of proteins which do not have any high-confidence interactions in the
ConsensusPathDB. The risk status is defined by the variants within TFBSs that
are either risk-inducing, risk-reducing (protective), a combination of risk-inducing
and risk-reducing (mixed) SNPs. If neither risk-inducing nor risk-reducing variants
are known, the risk status is neutral.
The four disease-associated proteins CTCFL_HUMAN, SIX5_HUMAN, SP4_HUMAN,
and SP2_HUMAN did not have any high-conﬁdence interactions in the ConsensusPathDB
(version 31). Table 3.21 shows the disease status of these four missing proteins.
In addition to the centralities, the assortativity of nodes of diﬀerent risk status has
been determined. In all cases the assortativity is close to zero and therefore does not
indicate grouping or anti-grouping of nodes of the same risk classes.
Chapter 4.
Discussion
“This was a triumph! I’m making a note here: Huge success!
It’s hard to overstate my satisfaction.”
— Mad robot GLaDOS (Lyrics)
Networks are about connections. The interactors themselves are certainly relevant,
but a far greater and more important challenge lies in determining which interactions
play a role in a phenotype and what their eﬀects are. Reference databases list plenty of
interactions but the context in which these interactions have been observed is often not
clearly documented or researched48.
In the course of this thesis many networks have been created. But only a selection
is presented. Especially networks of great complexity have been left out because they
are too diﬃcult to visualize and too diﬃcult analyze directly. But even the networks
presented in this work have many nodes and edges and therefore only a selection of nodes
and edges will be discussed in detail.
4.1. Biology of Inflammatory Diseases
When considering the genes, networks and term enrichment results, it appears that
regulation and signaling are the central aspects that matter in the diseases. Cellular
communication is responsible for the coordination of many intra- and intercellular
processes98. It is plausible that this regulatory machinery is not reacting correctly to
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external or internal stimuli. In the case of IBD there is accumulating evidence that the
disease is a result of an inappropriate inﬂammatory response to intestinal microbes22.
There exist several mechanisms to downregulate immune responses, including down-
regulation of inﬂammation by IL-1021. T-cells have a PD-1 receptor that leads to their
inactivation upon binding. Cancer cells exploit this receptor to neutralize T-cells99. Some
medications that interfere with this exploitation have side eﬀects that lead to overre-
actions of the immune system and some cases were reported where patients developed
psoriasis100. This underlines the potential importance of signaling and regulation in
inﬂammatory or immune-related diseases.
The enrichment results also clearly indicate that the immune system is a major factor
in these diseases even when a background correction for the Immunochip is used.
Regulatory T- and B-cells22 but also macrophages and monocytes21 appear to play a
major role in inﬂammatory diseases. These immune cells secrete and react to diﬀerent
cytokines. Macrophages are especially susceptible to regulatory signaling molecules and
exhibit very diverse behaviours depending on the tissue and the cytokines they are
exposed to21. This fact alone indicates that we need a better resolution on the tissue
level when we want to understand inﬂammatory diseases better. This thesis does not
try to take into account the diﬀerent tissues and the diﬀerent cells in the human body.
Although DEPICT makes use of gene expression data and performs tissue enrichment.
It detected many immune cells for all ﬁve diseases but it failed to detect the known
aﬀected organs of ankylosing spondylitis (spine), psoriasis (skin) and primary sclerosing
cholangitis (liver/bile ducts).
Inﬂammatory diseases are not the only diseases that are linked to (dysfunctional)
regulatory processes. Cancer is a category of diseases with aberrant signal processing98.
Some genes play a role in both types of diseases. For instance, JAK2 is a tyrosine kinase
that regulates cellular growth processes but it is also involved in signaling for innate and
adaptive immunity and many more signaling processes101. A similar common protein
is NFκB1 which participates in many biological processes18. Both proteins occur in
several networks shown in the results section. It is already known that inﬂammation
is a common observation in cancerous tissue98. The same pathways might be active in
inﬂammatory diseases and cancer. However, the enrichment listings in this thesis do
not show any cancer-related results. But some of the protective transcription factors are
known to be involved in cancer-related pathways: CTBP2, ESR1 and SIRT6. It is also
known that patients with ulcerative colitis have an increased risk of colorectal cancer102.
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Some studies have shown a connection between the nervous system and regulation
of inﬂammation103;104. Martin-Subero et al. report a high comorbidity of depression
and inﬂammatory bowel disease105. They state that depression is linked to immune-
inﬂammatory, oxidative and nitrosative stress pathways which also includes gut-brain
pathways. They also state that these pathways are relevant for IBD. However, the
analyses presented in this thesis did not detect any obvious neurological pathways,
mechanisms or genes.
Khor et al.23 describe six IBD genes that are related to the epithelial barrier. But
only one of these genes was detected in the context of this thesis: ERRFI1. This gene
is present in the (mostly) unconnected DEPICT subnetwork when using SBM p-values.
The enrichment results did not indicate that epithelial barriers plays an important role in
IBD even though it obviously is important. An explanation could be that that the clinical
symptoms of the epithelial barrier are mainly determined by environmental factors and
less by genetics.
Apoptosis is another common enrichment term. It is known that mucosal T-cells can
have increased resistance against apoptosis106. On a related note, Inﬂiximab is a drug
given as a treatment for several inﬂammatory diseases. This drug induces apoptosis in
T-cells25. However, the role of apoptosis in these diseases still seems to be unclear.
Further discoveries may change our perspective on these diseases. A common view
is that these diseases are seronegative, that is, there are no autoantibodies involved in
these diseases10. Very recently Quaden et al. describe the discovery of autoantibodies in
AS. More interesting ﬁndings may follow.
4.1.1. Networks of Inflammatory Diseases
Most disease-associated SNPs only increase or decrease the risk for developing a disease
by a low amount. The combined eﬀects of several SNPs and environmental factors
is probably required to cause the diseases1. This thesis attempts to ﬁnd connections
between SNPs to see which SNPs aﬀect genes and how these genes (or proteins) interact
with each other.
Most of the used SNPs lie outside of coding regions. They might act as expression
quantitative trait loci (eQTL) that aﬀect the level of gene expression of genes which
is a common phenomenon for disease genes107. Diﬀerent levels of expression may in
turn change the strength of a regulatory signal and cause overreactions or insuﬃcient
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reactions23. For instance, defective TFGβ signaling is known to impair the transformation
of pro-inﬂammatory monocytes to inﬂammation-anergic macrophages21.
A considerable overlap can be observed between the genes that are associated with the
investigated diseases (Figures 3.18 and 3.37). This is only partly surprising because there
is already a large overlap between the SNPs that are associated with the ﬁve diseases. A
superﬁcial comparison with multiple sclerosis shows that JAK2, STAT5A, ETS1, SOCS1,
IL12B, CD40 and other genes are shared with some of the ﬁve diseases16. This indicates
that there are more commonalities between inﬂammatory diseases. Goh et al. present
the diseasome network which shows that many genes are relevant to several diseases44.
The disease-speciﬁc subnetworks with less than ﬁve diseases (Figures 3.19 to 3.22)
are mostly unconnected. Only the network that contains nodes that are associated with
exactly one disease has one larger connected component that is speciﬁc to genes associated
with Crohn’s disease. One notable node of this component is EP300 which is responsible
for histone acetyl transfer108 and which is relevant for autophagy108. Therefore EP300
ﬁts well to Crohn’s disease29. However, the remaining nodes in this component are rather
dissimilar and provide no obvious explanation why they might be relevant for CD.
The HLA/MHC region on chromosome 6 is highly associated with inﬂammatory
diseases109;24. However, due to high linkage disequilibrium and high variance in the
population it is even more diﬃcult to map signiﬁcant variants to genes and to impute
genotypes110. It was observed that the MHC region had a major inﬂuence on the genes
that VEGAS choose to be signiﬁcant (Table 3.2). The MHC genes are a crucial part for
the interaction between host and microbes and a better understanding on how the MHC
region aﬀects genes is desirable to construct networks that represent the mechanisms of
the diseases better1.
Networks consist of nodes and edges. A causative SNP can either aﬀect nodes or
edges. That is, the SNP can either aﬀect the function of a single gene/protein/RNA
molecule or it can aﬀect the interaction between two molecules. It is already diﬃcult to
determine the causative variant, but once it has been identiﬁed, it should be determined if
the eﬀect directly inﬂuences a node or if it inﬂuences an edge in the network. Making this
distinction might oﬀer a better understanding of the wider eﬀect(s) that the SNP induces.
But then it still has to be understood if the causative variant impairs or improves the
biological process that it inﬂuences.
For instance, it is known that SOCS1 inhibits JAK218. This interaction has been
most notably observed in Figure 3.37 and it probably plays a role in CD and UC. In
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the same ﬁgure there is also the Toll-like receptor 4 (TLR4) on the far right. It is
involved in the innate immune response to bacteria and is therefore a good example for
an immunological protein/gene that works at the interface between host and microbes.
According to DEPICT it is only associated with CD but some publications indicate
that it also plays a role in psoriasis111 and ulcerative colitis112 while others found no
association for AS113 and for PSC114. Therefore DEPICT might have missed more disease
associations. TLR4 is known to be involved in many other diseases104.
Another well-known example of an immunological interface protein is NOD2 which
was detected by the DEPICT-based workﬂow but which has no neighbours in the network
(Figure 3.38, top row). NOD2 was correctly identiﬁed as a CD-associated gene115.
In the analyses of the eﬀect directions of SNPs some exclusively ”protective” genes
were found for some diseases. However, these genes are DNA-binding elements, that
bind close to or at the same position as a SNP. They are not the genes regulated by the
TFBSs. These binding proteins might be a lot less disease-speciﬁc than the actual genes
regulated by the TFBSs. But if a variant does indeed aﬀect the binding of a factor, then
this could be relevant for the development of diseases.
4.1.2. Representation of Biology in Networks
A common observation of protein-protein interaction networks is that there is one large
connected component and several smaller components of relatively low size46. This
observation was also true for most of the networks that were observed in this study.
It is plausible that several diﬀerent cell types are involved in the etiology of inﬂam-
matory diseases. We currently do not have a good resolution on the cell-type level to
see which cell types are aﬀected by which SNPs. The real biological networks might
even span several diﬀerent cell types which seems plausible given that signaling is a
common theme in the networks. In addition, there are further dimensions to consider
when looking at protein-protein interactions: Proteins can be in diﬀerent states due
to chemical modiﬁcations like phosphorylation and they can have diﬀerent amino acid
sequences due to alternate splicing. These factors can inﬂuence the binding and the
activity of proteins6.
Various ﬁltering methods (including subnetwork generation methods) were applied
to the networks which resulted in singleton nodes without any connections. Under the
assumption that these singletons are truly associated with a speciﬁc disease we either
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lack interaction knowledge to connect these nodes to the rest of the network or the
disease-causing role of such a node does not involve protein-protein interactions.
A central problem of network analyses is the biological interpretation of the connections.
Especially in greater networks there are a lot of possible pathway ﬂows that have to
be considered. Semantic and causative annotations for interactions between nodes like
those from the openBEL project116 could help to understand the networks as a system
of dependent interactors.
For protein-protein interaction networks the direction of the edges are not known. An
interaction denotes an observed binding of two proteins but many times it is unknown
what the eﬀect of the binding actually is and which protein is being regulated and which
protein is a regulator. The Hippie PPI database tries to create directed PPI networks by
taking a list of source nodes (starting nodes) and a list of sink nodes (target nodes) and
determines the shortest paths between source and sinks nodes and assigns directionality
along the shortest paths117. However, it is still the responsibility of the user to provide a
correct list of source and target nodes for the network which is far from trivial.
A common goal of network analysis is ﬁnding new disease genes. This is usually
achieved by selecting known neighbours of disease-associated nodes. This was done in
the context of various analyses and in most cases the size of the networks drastically
increased and it was diﬃcult to get a clear picture of the situation. Enrichment analyses
helped to characterise the neighbouring genes but overall too many genes were added to
the network. Thus the principle guilt-by-association is problematic when dealing with too
many neighbours. To compensate for the many linker genes, a prioritisation of the linker
genes was attempted in section 3.2.6 by scoring linker genes higher that had a high ratio
of disease neighbours to non-disease neighbours. Among these genes are IL23A, which is a
subunit of the IL23 cytokine118 which in turn interacts with the highly disease-associated
IL23 receptor118 (IL23R) (disease association with AS, CD, PS and UC). This makes it
a clear candidate for being relevant for these diseases. IL12RRB1 (I12R1_HUMAN) is
another interactor of the just mentioned IL23R118. ITGAL is a linker gene for PS and
it is another receptor component that is involved in cell adhesion and immune system
processes, including inﬂammation119. It is expressed in all leukocyte lineages119 and it
is already associated with AS and UC. IRF6 is has only two connections, both which
are UC-associated. It is involved in cell cycle regulation120. FGFR3 is a tyrosine-protein
kinase121 and it is linked to two UC genes. It is activated by the MAP kinase cascade
and STATs121. FGFR3 activates the SOCS1 and SOCS3 (SOCS=suppressors of cytokine
signaling)121. SOCS1 is linked to JAK2 in the DEPICT-based network (Figure 3.37)
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conﬁdence). One example for such a protein is the estrogen receptor (ESR1_HUMAN)
which we have encountered previously in this thesis (section 3.3.3). While this agrees
nicely with the small world phenomenon, it does not always do justice to the biological
reality. In real biological systems certain conditions have to be met to make it possible
for an interaction to take place. In the simplest case both interactors have to be in the
same cellular compartment to interact. A challenge of network science is to understand
these conditions and eliminate edges that are not relevant under the given conditions82.
4.2. Mapping of SNPs to genes
For most SNPs it is still unknown which genes they aﬀect. In addition, linkage dise-
quilibrium makes it diﬃcult to determine the actual causal variant for diseases because
unrelated variants are inherited together with the causal variant.
Various approaches exist to map SNPs to genes. VEGAS is a popular choice48.
However, the reliability of the tool is uncertain due to the fact that VEGAS turns oﬀ
warnings in its code which might otherwise be helpful to discover problems. Furthermore
VEGAS uses the corpcor R package to create positive deﬁnite matrices, but the package
does not always succeed in creating proper positive deﬁnite matrices and VEGAS changes
the resulting matrices on its own by overwriting entries along the diagonal with input-
unspeciﬁc constants. Another strange observation is that VEGAS produces gene-wise
p-values of magnitude zero during its calculations. The authors state that this is due to
”computational reasons” which is not further elaborated. The smallest non-zero 64-bit
ﬂoating point number that R can work with is 10−323 which is very precise. The smallest
non-zero p-value that VEGAS produced in all analyses was 10−6 which is still very far
away from the potential 10−323 that can be represented on a modern computer. This
strange behaviour could therefore be the result of a software bug.
The VEGAS paper states that a p-value of 10−6 is suﬃciently signiﬁcant because
it is below the Bonferroni-corrected threshold of p < 2.8× 10−6 62 and at this level no
additional attempts are made to reduce the gene-wise p-value even further. Still, this
leads to a lot of genes having a p-value of zero and a lot of p-values having a p-value of
10−6. The IMSGC relied on these p-values to prioritize genes to generate submodules
with the Cytoscape plugin jActiveModules.
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There are several successors to VEGAS. Among them are VEGAS 2, and PASCAL124.
VEGAS 2 was still in development when it was tested with our data. VEGAS 2 showed
the following behaviour: All genes in the result set had the same p-value. When using
VEGAS 1 with the same list of SNPs diﬀerent gene p-values were reported. PASCAL is
a newer software which has not been evaluated yet. According to the authors, PASCAL
outperforms VEGAS and is also able to handle p-values smaller than 10−6.
A simpler approach to gene-mapping is to determine the linkage region of a lead SNP
and incorporate all genes that lie within that region for further analysis. This approach
is simple and fast. Pers et al. determined that a linkage distance of r2 > 1
2
is a good
choice for the size of a linkage region51. Further prioritisation of genes within each region
can be performed. For instance, DEPICT tries to ﬁnd combinations of genes from all
regions that are as closely related as possible. The idea behind this seems plausible. All
of these SNPs have something to do with a speciﬁc disease. Therefore all genes aﬀected
by these SNPs should also have something to do with a speciﬁc disease and share some
commonalities.
However, the eﬀects of SNPs can be remote. A good example are distal transcription
factor binding sites which might change their binding aﬃnity for transcription factors.
This binding aﬃnity can increase or decrease the rate of translation of a gene. That is
why using annotations like those from the ENCODE project appear to be a good idea to
determine which transcription factors (and, if it is known, which genes) could be aﬀected
by distant variants that lie far outside of proximal linkage regions. A considerable overlap
between distal TFBS and SNPs was observed in this project indicating that distal TFBS
might play a role in these diseases. However, GoShifter also tries to assess whether the
overlap of all LD SNPs with an annotation is by chance. Unfortunately the GoShifter
paper does not give a good guideline what threshold should be chosen for a good score
and therefore no ﬁltering was done in the work presented here. This might have led to
more false positives. Another problem is that GoShifter only gives a score to the lead
SNP but not the LD SNPs so that all LD SNPs have to be taken into account for further
analysis.
An observation that was made throughout all analyses is that the number of SNPs
that are known for a disease directly aﬀects the number of genes that will be marked
as potentially associated. Crohn’s disease and ulcerative colitis are considerably more
researched than the other three diseases. This in turn might lead to imbalances when
it comes to reasoning about how these diseases manifest themselves on the network
level. There might be more SNPs that could be relevant for the other diseases. Current
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GWAS studies use imputation instead of complete sequencing and are unable to discover
completely new variants23.
On the ﬂip side, less SNPs could make the analysis simpler. It is known for the ﬁve
diseases that there are subtypes of each disease2. Each subtype might have a diﬀerent
genetic proﬁle and distributing the SNPs among the proﬁles could make understanding
the etiology of the diseases easier. Given the multitude of genetic factors and yet to be
discovered environmental factors, there is probably not a single etiology but several.
But even knowing a causal variant might not directly lead to an understanding of
how that causal variant inﬂuences the development of disease because in the case of
transcription factor binding sites there can be several transcription factors that bind to
that site of 150 base pairs according to ENCODE. Almost all TFBS encountered in this
work were of size 150bp. Four TFBS were 290bp or 270bp long.
Using ENCODE annotations that list transcription factors that bind to speciﬁc regions
appears to be the most reliable way to link SNPs to genes/proteins, simply because the
annotations are manually curated. The problem with this approach is that this only
captures SNPs that potentially aﬀect the binding of transcription factors. Therefore a
combination of diﬀerent mapping methods is advised to get the most realistic results.
Overall it was observed that many LD SNPs are indeed located at TFBS and might
act as eQTLs that aﬀect the eﬃciency of starting transcription. This would ﬁt well with
the small eﬀect sizes because these SNPs could disturb the initialisation of transcription
and make certain pathways less eﬃcient without rendering them totally nonfunctional.
But a combination of several genetic factors could create enough disturbances that it is
more likely that functionality is critically impaired and disease develops.
It should also be noted that the calculation of odds ratios and thereby the risk
classiﬁcation of SNPs might not be reliable because evolutionary young causal variants
have a diﬀerent allele distribution in the population than evolutionary old causal variants14.
Furthermore, in complex diseases, a combination of several speciﬁc SNPs might be required
for the disease to develop so that many healthy individuals can carry individual risk
genes but they do not get the disease because the required combination of genetic factors
is missing14. These issues can lead to actual risk variants being classiﬁed as protective
and vice-versa14. In addition, unknown environmental factors might further skew the
association results.
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The approach to map SNPs to DNA binding elements (transcription factors) revealed
that there is only a small overlap of nine genes between the genes prioritised between
DEPICT and the binding elements from ENCODE. This might simply be due to the
fact that both approaches are inherently diﬀerent. The DEPICT approach works with
genomic proximity of SNPs to genes while the ENCODE annotations provide a list of
proteins that bind to the region of the SNP. These proteins in turn can be located at any
position within the genome, including diﬀerent chromosomes. But still, it is a plausible
explanation that SNPs inﬂuence the eﬃciency of transcription. Such an inﬂuence could
be modelled as an edge in the network between a transcription factor and the gene that
is regulated by it. Transcriptional regulation seems to be a neglected phenomenon in the
ﬁeld of inﬂammation-related networks.
In general there are many diﬀerent ways a SNP could potentially aﬀect biological
function37. There is probably not a single approach that does justice to all of these
diﬀerent ways. Future work should try to take into account known locations of non-mRNA
coding regions because these might also play a role.
4.3. Construction of Networks
All analyses in this work used the ConsensusPathDB because it is a metadatabase that
consolidates protein-protein interactions from several databases. There are alternative
PPI metadatabases like the iRefIndex database which could also have been used but the
ConsensusPathDB was chosen because of prior good experience with it and because it
was recommended by external scientists.
Diﬀerent versions of the CPDB have been used throughout this work because newer
versions of the database were released over time. Initially an edge conﬁdence threshold
of 90 percent was used to have less false negative interactions but given the sheer size of
interactions the conﬁdence threshold was increased to 95 percent which still yielded a
great number of interactions.
However, biology is much more complex than just protein-protein interactions. The
vast majority of GWAS-network analyses use protein-protein interactions125;126;127 because
they are freely available and quite extensive48. But to fully capture molecular networks
it is necessary to incorporate further types of interactions like transcription factor
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binding interactions, microRNA-mRNA interactions and other types of regulatory RNA
interactions.
It should also be noted that proteins can be in diﬀerent states due to splicing6,
post-translation modiﬁcations (glycosylation)6 and chemical modiﬁcations like phos-
phorylation6 which can inﬂuence how and if a protein interacts with other proteins128.
Therefore a better resolution about the states of proteins during binding is desirable.
4.3.1. Finding subnetworks and submodules
Only a fraction of the interactome is relevant for the diseases under investigation.
Therefore the networks have been ﬁltered down to contain only the genes/proteins
that were determined by mapping the SNPs to genes. Given that all ﬁve diseases are
genetically complex diseases, the subnetworks of these diseases were still too complex to
directly analyse with the exception of the networks derived from the DEPICT genelists.
A popular approach is to ﬁlter subnetworks down to modules. This approach is
implemented by the Cytoscape plugin jActiveModules. However, the algorithm behind
jActiveModules was originally developed to detect modules of genes with diﬀerential
gene expression and not modules of GWAS genes. These are two very diﬀerent settings.
Expression analyses experiments usually have a very limited set of stimuli that change the
expression of some genes. In the case of GWAS lists a lot of genes from diﬀerent contexts
are part of the network. However, Ideker et al. also tested jActiveModules with 20
diﬀerent simultaneous known pertubations in yeast and came up with a submodule of size
340 which they considered to be ”extremely large” and to be diﬃcult to analyse visually.
They broke down this submodule even further by recursively applying jActiveModules
on it. Figure 4.2 shows the submodules that Ideker et al. obtained from the large
yeast interaction network. It can be observed that the submodules are almost tree-like,
i.e. there are only few circles within the network. The submodules presented in this
thesis have more connections in the larger connected components. The submodules
obtained by the IMSGC also appear to have a diﬀerent structure with more cycles than
Ideker et al. (Figure 4.3). It is uncertain if these network structures are due to the fact
that jActiveModules was originally developed for diﬀerential gene expression analyses.
jActiveModules assumes that the nodes inﬂuence each other in a chain of interactions.
This assumption does not hold true for GWAS genelists. Mapping SNPs to genes is
diﬃcult and it is likely that the genelists are incomplete and contain false positives.
Furthermore, diﬀerential gene expression experiments try to measure causal relationships
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It was hoped that the enrichment analyses would also turn up known pathways.
DAVID supports enrichment for KEGG pathways but these never showed up in the
results. However, gene ontology terms for the JAK-STAT pathway were enriched in
several cases.
DEPICT also does enrichment to ﬁnd the best consensus among genes. It detected
several genesets which have names of the from ”G PPI subnetwork” where ”G” is
some gene. These subnetwork-genesets are increasingly common the fewer diseases are
speciﬁcally associated with them: Figure 3.25 lists many such subnetwork genesets while
ﬁgure 3.29 lists only one: The subnetwork that is common for all ﬁve diseases is the IL2
subnetwork. IL2 is involved in the regulation of the T-cell based immune response130
and it is plausible that it is relevant for all of these inﬂammatory diseases. Other
subnetworks detected by DEPICT are also relevant for immune system function. The
KIT PPI subnetwork is a diverse signaling network which also inﬂuences STAT signaling.
Some surprising terms are the MRPL44 and MRPS14 subnetworks because MRPL44
(RM44_HUMAN) and MRPL44 (RT14_HUMAN) are components of the mitochondrial
ribosomes131. The MRPL44 term is exclusively enriched for the diseases AS, CD and
UC while the MRPS14 term is exclusive for UC132. Other subnetworks include the
BID subnetwork that is relevant for apoptosis, which is also a common enrichment term
detected by DAVID. The connection between inﬂammatory diseases and apoptosis is
well known133.
When dealing with a list of genes, enrichment analyses are a convenient approach to
get a quick overview on common functionality of these genes. However, a closer inspection
of the genes is still needed to understand their role in disease61.
DEPICT also performed a tissue enrichment based on expression proﬁles from existing
background data. The results do not appear to ﬁt the diseases well. For ankylosing
spondylitis there should be enrichment for bone tissue, for psoriasis there should be skin
tissue and for primary sclerosing cholangitis there should be liver or bile tissue but these
were not observed for these diseases. However, this is not a new observation. In the case
of AS it has been previously noted that genes determined through GWAS are not known
to be involved in the ankylosing process of the spine24.
In contrast the tissues enriched for Crohn’s disease and ulcerative colitis included parts
of the gastrointestinal tract. All diseases had enrichment for blood and immune-system
related tissues which makes sense for inﬂammatory diseases. But overall there are many
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mismatches between the organs known to be aﬀected by a disease and the enriched
tissues.
Li et al. report a pathway association of IBD with the EGF pathway69 based on
enrichment analyses. They used VEGAS to map SNP p-values to gene p-values. They
chose a signiﬁcance threshold of 0.05 to distinguish between ”signiﬁcant genes” and
”nonsigniﬁcant genes”. However, they also state that only few of the 18 genes from the
EGF pathway are highly signiﬁcant which makes an enrichment less strong.
DEPICT detected ”EGFR PPI subnetwork” as an enrichment term that was only
associated with Crohn’s disease (Figure 3.25) but it was a weak signal and several other
subnetwork terms were also detected. Apart from this ﬁnding there is no considerable
signal for the EGF pathway in the results.
The genes that DEPICT determined where enriched for terms that are related
to signaling and regulation. It should be kept in mind that DEPICT tries to ﬁnd
genes that are similar when mapping SNPs to genes. This could in principle cause
a bias in the enrichment results. However, the categories ”signaling” and ”regulation”
were determined as meta-enrichment terms based on manual inspection of the various
enrichment results. Diﬀerent terms like transcription factors and protein receptors
describe diﬀerent mechanisms of regulation.
DEPICT scored the genes and the highest-scoring genes for each signiﬁcant recon-
stituted geneset can be seen in ﬁgures 3.25 to 3.29. The gene with the highest overall
score is GPBAR1 within the genesets cell activation in immune response and leukocyte
activation involved in immune response. GPBAR1 is a receptor for bile acids. It has
the highest score for Crohn’s disease while the score for PSC is rather moderate even
though bile acid is much more ﬁtting for PSC than for CD. It is hypothesized that it
is involved in the suppression of macrophage function by bile acids134 which makes it a
good candidate for a disease gene in inﬂammatory diseases.
GoShifter is another form of enrichment which tries to assess whether an overlap of a
set with SNPs in a linkage region with genomic annotations is by chance or a real signal.
Downsides of this approach are that it is not clearly deﬁned where to put the score cutoﬀ
(the corresponding paper72 presents a hit with a score of 10%). Furthermore, the score
is only assigned to the lead SNP even though it is often the LD SNPs that have an
overlap with the annotations. GoShifter produces a global p-value for all p-values and
all annotations together. This global p-value can be signiﬁcant (Table 3.17) even if many
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scores of the individual lead SNPs are only moderate. This makes the interpretation of
the results challenging.
4.5. Methodological Considerations
Going from GWAS SNPs to network submodules requires several steps. Each of these
steps has uncertainties that harbour the danger of failing to transfer important information
to the next step but also to transferring irrelevant information and thereby increasing
the noise in the results.
And once a result has been obtained it is often impractical to validate it directly
because it would require expensive experiments135;14. To date there is no complex disease
that has been suﬃciently well understood so that it is possible to create analysis pipelines
that are validated with the disease. But even with such a validated pipeline there would
probably still be the need for exploratory analysis.
In their review Jia et al.48 enumerate various categories of network analyses (see
section 1.5.3). But they do not explain in which situations one type of analysis should
be preferred over another. Based on the independent categories they describe, a total of
24 × 3 = 48 diﬀerent types of approaches to analyse networks are possible. And each of
these approaches has further parameters and data sources that need to be chosen. Each
choice has the potential to change the results.
In wet labs experiments there are usually positive and negative controls to determine
if an experimental procedure worked correctly. This is something that is still mostly
missing in network science of inﬂammatory diseases. We know about certain pathways
that are involved in IBD, like JAK-STAT signaling101. We also ﬁnd JAK-STAT signaling
in our data which to some extent serves as a positive control. But with so many genetic
factors more positive controls would be desirable and negative controls to detect noise
would also be very helpful.
The is currently no gold standard for mapping SNPs to genes and genesets12 and it
is still an open question how to do this properly. For coding SNPs the answer is trivial,
but even then it is still conceivable that such a SNP may have additional eﬀects on
RNA-related regulation.
With these problems in mind, network workﬂows can still serve as a method to
generate hypothesises in the context of the genetics of inﬂammatory diseases.
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4.5.1. Automation, Reproducibility and Repeatability
A common method to ”validate” results is to create random results and to determine
the similarity of the real results to the distribution of random results. If the real result
is signiﬁcantly diﬀerent from most of the random results it can be assumed that these
results did not just occur by chance. However, the biological relevance of the results is
still not proven.
When generating such random results it would be desirable to store the random
results in a ﬁle so that it is possible to reproduce the signiﬁcance of the real results in the
future deterministically instead of randomly. Even if converging random processes like
Monte Carlo simulations are used, there will still be minor diﬀerences in the results136
that can later lead to uncertainty about successful reproduction.
GoShifter uses randomness internally and when it is running it prints the random seed
used to generate the random numbers. But there is no way to provide such a random
seed to GoShifter to make it run deterministically. Other tools used for this thesis that
make use of randomness include VEGAS, jActiveModules and PINBPA and they provide
no facilities to control randomness.
In scientiﬁc work it is helpful to automate as much as possible. This makes it possible
to improve details in a data processing pipeline and to automatically perform all the
steps that are needed to compute an updated result. Graphical tools like Cytoscape
have the fundamental problem that they are not fully scriptable and therefore not all
workﬂows can be automated. Automation scripts also implicitly document the steps that
were performed with the data. Even if complete reproducibility cannot be guaranteed,
automation provides a way to ensure repeatability137 of the steps that were performed
and to inspect every step for errors.
Given that exploratory data analysis is required for network analyses, the Jupyter
notebook proved to be a valuable tool to directly execute data transformations but
also write a rationale for every step directly alongside the transformative code. This
strikes a good balance between exploratory analysis and full automation while still
documenting each individual step and the thought process so that it is later possible
to follow the reasoning of the individual analysis steps and potentially ﬁnd ﬂaws. The
relevant notebook sessions are attached to this thesis as supplementary data.
A central problem of reproducibility is software dependencies. A software called dmG-
WAS138 appeared to be a promising tool to work with GWAS data and networks. But
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dmGWAS depends on the igraph library139. After the oﬃcial release of dmGWAS, this
library changed its behaviour regarding indexing of arrays (zero-based versus one-based).
This made dmGWAS unusable because the original assumptions in the dmGWAS code
regarding indexing were no longer true. A remedy to this problem is to package up
scientiﬁc software together with all dependencies. The Docker virtualisation infrastruc-
ture140 appears to be a good solution for this because it makes it possible to bundle
all needed software dependencies at a speciﬁc version together with the main software
as one package of moderate size. Docker has been used for some parts of this work
(GoShifter, DEPICT, Jupyter Notebook) but it will not be discussed in detail because it
did not aﬀect the scientiﬁc results themselves and is also unlikely to aﬀect the speed of
the computations140.
4.6. Future work
Complex diseases are the result of many diﬀerent factors working together. Unfortunately,
we only have a limited resolution on the genetic level when it comes to causative variants.
Furthermore, environmental factors also play a major role that should be taken into
account if possible.
Given the great number of factors it is unlikely that all factors are involved in every
case when a disease develops. In fact, not every patient carries all disease variants. The
etiology should therefore rather be inspected on the individual level: Which risk factors
does a patient actually have? Where do these factors occur on the network level? It is
very likely that there are several diﬀerent etiologies for these diseases and it is therefore
diﬃcult to consider them all at once.
It is well known that there are diﬀerent subtypes of these diseases141;26. A better
stratiﬁcation between patients with diﬀerent subtypes could lead to a drastically simpler
picture. But then again, the knowledge about the individual subtypes of patients might
simply not have been recorded when collecting data for the studies.
When working with the genetic proﬁles of individuals, the actual SNPs can be mapped
into a gene/protein interaction network. This network might be sparser with disease genes
than the networks presented in this thesis. It is likely that several factors act together to
cause disease. In logical terms this can be expressed as an AND conjunction. One approach
to predict such conjunctions would be to determine the nearest disease node neighbour(s)
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of every disease node. Then a combined risk score could be calculated to see if the
combination of these neighbouring SNPs is signiﬁcantly more or less common in people
who have the disease in contrast to those who do not have it. Other factors are independent
of one another and they could be expressed in a logical OR disjunction. Predicting such
disjunctions could be done by overlaying the networks of individual patients and controls:
Every disease node in one patient tries to ﬁnd the nearest neighbour(s) that are not
disease nodes in the current network but are marked as disease nodes in one of the other
patient networks.
Another approach to simplify the analysis would be to cluster patients based on their
genotypes. This way it might be possible to stratify for diﬀerent disease subtypes on the
genetic level.
We know that the odds ratios or risk scores of SNPs are only providing a tendency
for developing the disease. The just described approach does not try to express the
chance of developing a disease in boolean terms. But it tries to capture the assumption
that genetic factors act together or can act independently while still causing similar
phenotypes. The relationships between these connected genes could then be more closely
investigated because they might provide additional understanding how the diseases work.
Special attention should be given to genes that act at the interface between host and
microbes and genes that are known to be aﬀected by smoking. The connections between
genetic factors and environmental factors should be more closely investigated.
When mapping SNPs to genes, a combination of diﬀerent approaches/tools should be
used because diﬀerent approaches are able to capture diﬀerent genomic structures better.
For every single SNP it should be decided which approach yields the most plausible
biological association and then use that association for the mapping to genes. In the case
of transcription factor binding sites, it should be attempted to determine both, the gene
and the transcription factors that bind to this site.
It could also be attempted to use disease-associated chromatin and histone marks
to determine further genes that may be regulated by them. And it should also be
investigated if there are any overlaps of SNPs with areas that code for long non-coding
RNAs or other types of RNAs because it has already been shown that microRNAs play
a role in Crohn’s disease142.
Future network analyses should in general focus much more on the edges between
genes and less on the nodes themselves. Every true edge describes a biological process
or function. There is the problem of false positive edges that describe non-existing
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interactions or interactions of biological irrelevance (i.e. interactions that do not have
any notable eﬀects on the capability of the proteins to execute their functions). It is
therefore important to develop methods that prioritise edges and remove edges of less
importance from the network. One such approach could be to assign a score to each
edge depending on how many GO terms the connected nodes share normalized by the
background distribution of these GO terms. Removing edges has also major advantages
for visualizing networks because well-connected networks tend to form complex clusters
that are visually hard to dissect.
There are more inﬂammatory diseases that could be investigated in relation to the
ﬁve diseases to get a better understanding of what is really typical for inﬂammatory
diseases. The ﬁve diseases studied in this thesis have been chosen because they are very
similar to each other on the genetic level1. A comparison with more distantly ”related”
diseases could provide further insights on common and diﬀerent disease mechanisms.
This thesis also presented some interesting candidates for new disease genes based on
the principle of guilt-by-association (section 4.1.2). A closer investigation of these genes
could be of interest.
And ﬁnally a combination of diﬀerent reference networks should be used to create
networks that include not only protein-protein interactions but also transcriptional
regulators and translational regulators.
Chapter 5.
Conclusions
“We do what we must because we can. For the good of all of us. Except
the ones who are dead.”
— Mad robot GLaDOS (Lyrics)
When constructing networks, we try to establish a digital approximation of what
biology is like. Establishing a good approximation is a real challenge, because we often
do not have a good enough resolution on the molecular level to understand which
components interact and how they interact. But further research will continuously add
more observations and might provide a better understanding of the mechanisms behind
the diseases.
The observations made in this thesis indicate that the biology of the diseases is
dependent on signaling and regulation to a large degree. This conforms well with the
common assumption that - at least in the case of inﬂammatory bowel disease - the disease
is caused by an aberrant immune response to environmental triggers143. It is plausible
that the cellular coordination in patients is not adjusted well and therefore the immune
system overreacts.
It is still unclear how to best link associated loci to genes. And this is the foundation
for all further network analyses. More research is needed to understand DNA-based
regulatory mechanisms better in general.
PPI networks tend to be noisy and contain many edges that are probably not relevant
for the biological phenomenon in question. A better understanding on how genes/proteins
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work together would be helpful, to prioritise putative relevant edges to get a clearer
picture on the network level.
Therefore it can be concluded that the overarching primary aim with the networks is
to get a good signal-to-noise ratio. After that, the next challenge is to understand the
biology in the networks. Depending on how much is already known about the interactions,
this might be a feasible endeavor. But there are still a lot of gaps in our knowledge about
molecular biology that we need to ﬁll in.
Further research needed.
Appendix A.
Zusammenfassung
Die Genetik von fünf chronischen Entzündungserkrankungen wurde mithilfe von Netzwerk-
und Enrichmentmethoden untersucht. Viele Ansätze wurden ausprobiert um Netzwerke
bestehend aus krankheitsassozierten Genen zu konstruieren. Große Netzwerke wurden
in Teilnetzwerke aufgeteilt mit dem Ziel Module zu ﬁnden, die speziﬁsche funktionale
zelluläre Funktionen repräsentieren. Ein klares Bild gab es in der Regel nicht. Generell
konnte aber beobachtet werden, dass Regulation und Signalübertragung wesentliche
Konzepte der krankheitsassozierten Gene sind und weitere Forschung daher sich darauf
fokussieren sollte diese Signal- und Regulationsprozesse besser zu verstehen, um potentiell
herauszuﬁnden, wie die Gene Entzündungsprozesse und Interaktionen mit Umweltfaktoren
beeinﬂussen.
Mehrere nicht-Krankheitsgene wurden gefunden die direkt mit Krankheitsgenen
interagieren und daher genauer untersucht werden sollten, weil sie nach dem Prinzip
guilt-by-association gute Kandidaten für noch unbekannte Krankheitsgene sind.
Die fünf Erkrankungen, die in dieser Arbeit untersucht wurden, sind sich auf genetis-
cher Ebene sehr ähnlich. Diese Ähnlichkeit war auch auf der Netzwerkebene sichtbar.
Viele Gene sind möglicherweise relevant bei mehreren Krankheiten gleichzeitig und die
krankheitsspeziﬁschen Teilnetzwerke überlappen sich. Allerdings wurde nur im Falle von
Morbus Crohn ein größeres Teilnetzwerk gefunden, dass exclusiv nur für diese Erkrankung
speziﬁsch ist.
Wenn man die Eﬀektrichtung der SNPs für die einzelnen Erkrankungen berücksichtigt,
so wurden keine klaren Tendenzen im Zusammenhang mit den Lokus-assozierten DNA-
Bindeelementen (z.B. Transkriptionsfaktoren) auf der Protein-Protein Interaktionsebene
gefunden.
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Die Beobachtungen in dieser Arbeit bestätigen die gängige Sichtweise, dass das
Immunsystem eine wichtige Rolle bei der Entstehung der Krankheiten spielt, weil viele
Immunsystem-relevante Gene in den Analysen gefunden wurden und weil die Enrichment-
Ergebnisse dies ebenfalls bestätigen.
Appendix B.
Summary
The genetics of ﬁve chronic inﬂammatory diseases have been investigated with network
and enrichment methods. Various approaches have been tried out to construct networks
of disease-associated genes. Networks of great size have been split up into subnetworks
with the aim to ﬁnd modules that represent speciﬁc cellular functions. However, a clear
picture could usually not be obtained. But in general it could be observed that regulation
and signaling are major themes of disease-associated genes and further research should
therefore focus on understanding these signaling and regulation processes better to
potentially ﬁnd out how they inﬂuence inﬂammation or interactions with environmental
factors.
Several non-disease-associated genes have been found to be directly connected to
disease genes and should therefore be investigated more closely as they are good candidates
for being yet unknown disease genes based on the principle of guilt-by-association.
The ﬁve diseases investigated in this thesis are very similar on the genetic level. This
similarity was also visible on the network level. Many genes are putatively shared among
the diseases and disease-speciﬁc subnetworks overlap each other. However, only in the
case of Crohn’s disease there was a greater subnetwork that was speciﬁc to this disease.
All other diseases had no greater (> 3 nodes) exclusively disease-speciﬁc subnetworks.
When trying to take into account the eﬀect direction of SNPs for individual diseases,
no clear tendencies were observed when investigating the locus-associated DNA-binding
proteins (e.g. transcription factors) on the PPI-network level.
The ﬁndings in this thesis conﬁrm the common view that the immune system plays an
important role in the etiology of the diseases because many immune system-relevant genes
were found in the networks and the enrichment results also conﬁrmed their relevance.
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Supplementary Chapters
C.1. A few notes on the Microbiome
The microbiome is not a focus of this thesis. But it is still a very important biological
factor of several inﬂammatory diseases and is therefore worthy of a few notes to provide
a more complete picture of the relevant factors of the diseases presented in this thesis.
There are three large interfaces where human cells and microbes meet: The skin, the
respiratory tract and the gastrointestinal tract18. Microbes inhabit or come in contact
with these body regions and therefore every human contains a huge number of microbes
in its body. It is often said that the ratio between microbes and human cells is ten to
one144, but recently Sender et al. argued that these numbers might not be accurate and
suggest that the ratio should be one to one145. In any case, the human body harbours a
large number of microbes that can be commensal or pathogenic.
Many microbes have a symbiotic relationship with their human host. In the simplest
cases, their purpose is just to take up a niche so that no other potentially harmful bacteria
can colonize on the tissue146. Some bacteria also have immunomodulating abilities. They
regulate immune tolerance147. Then there are also bacteria that actively ﬁght pathogens
that could harm the host. In a sense, they are an extension of the human immune
system148. They also play major roles in the development and training of the immune
system19.
The human body consists of many diﬀerent organs which serve diﬀerent functions.
Organs that are open to microbes tend to have speciﬁc microbiome populations i.e. the
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bacterial species found in the large intestine diﬀer from the small intestine because each
of these organs is a diﬀerent ecological niche21.
It is very likely that humans need a healthy microbiome to be healthy. It is thought
that disruption or even extinction of microbial communities can have severe eﬀects on
the human body5. In patients with inﬂammatory bowel disease a common observation is
that the diversity of the microbiome is severely reduced147. Many microbes probably can
not survive the chronic inﬂammation in their host while other microbial strains are able
to deal with it and rise in numbers147.
It is unclear whether the lack of diversity is a cause or a consequence of inﬂammatory
diseases. Due to lifestyle it is conceivable that the immune system of humans in more
sterile environments has a lot less exposure to microbes in early years of life and is
therefore not properly trained to distinguish harmless microbes from bad microbes149.
However, it should also be noted that in inﬂammatory bowel disease the mucosal
barriers are repeatedly broken and microbes travel into tissue21. This in turn also leads
to inﬂammatory responses to kill oﬀ the invading microbes21.
C.2. Modifications to VEGAS
VEGAS62 was downloaded and installed locally. In order to run with our data it had to
be patched to avoid crashes. A reference to a user’s home directory had to be removed
from the source code. Furthermore, VEGAS makes use of the corpcor R package to
correct for non-positive deﬁnite correlation matrices. However, apparently this correction
does not always succeed because several parts of the VEGAS source code make additional
adjustments to the matrices:
l ibrary ( corpcor )
reps <− $_[ 0 ]
i f ( i s . p o s i t i v e . d e f i n i t e (co)==F){
co <− make . p o s i t i v e . d e f i n i t e (co )
}
i f ( i s . p o s i t i v e . d e f i n i t e (co)==F){
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matrix ( scan ( ’ p l i nk . ld ’ , qu i e t=T) , nc=numsnps ) −> co
for ( i in 1 : numsnps ){
co [ i , i ] <− 1 .0001
}
}
i f ( i s . p o s i t i v e . d e f i n i t e (co)==F){
for ( i in 1 : numsnps ){
co [ i , i ] <− 1 .001
}
}
i f ( i s . p o s i t i v e . d e f i n i t e (co)==F){
for ( i in 1 : numsnps ){
co [ i , i ] <− 1 .01
}
}
And there is no ﬁnal check for success. VEGAS crashed on our dataset. Adding the
following code removed the crash:
i f ( i s . p o s i t i v e . d e f i n i t e (co)==F){
for ( i in 1 : numsnps ){
co [ i , i ] <− 1 .1
}
}
While these ﬂaws in software design were some reason for concern, the mathematics
behind the algorithm could not be challenged and the tool is still widely used in the
research community68;69;16. For this reason it was still used for parts of this thesis.
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